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ABSTRACT 
 
 
 Current advances in the drug delivery have improved the therapeutic efficacy of 
the drug and minimized risks of side effects associated with toxicity of the drug. 
Implantable polymeric delivery system has gained increasing attentions for controlled 
drug release and localized treatments. In comparison to conventional chemotherapy, 
polymeric delivery systems are implantable at a local targeted site and biodegradable 
after a sufficient therapeutic span. The objectives of this project were to fabricate and 
characterize an implantable polymeric vehicle for a local chemotherapy and investigate 
its biological properties against cancer cells including human WM115 melanoma, human 
U87 glioblastoma, and rat C6 glioma cells in vitro and in vivo. 
 
 In this study, a natural chitosan polymer was employed as a drug vehicle and 
ellagic acid (EA), a naturally occurring phenolic compound, was incorporated as a 
therapeutic agent. The chitosan/ellagic acid composite films were developed by 
combining 1% (w/v) chitosan solution with different concentrations (0.05, 0.1, 0.5, 1, or 
20% (w/v)) of ellagic acid for a local chemotherapy. Characterization of composite films 
was performed on chemical structure, crystallinity, surface morphology, degradation 
behavior, and release profile. Cancer cell activity on the composite films was evaluated 
through direct and indirect cell culture using MTS assay. Anti-cancer mechanism of the 
composite films against cancer cells was investigated using apoptosis assay, caspase-3 
activation, western blot for p53, and anti-angiogenesis assays. In the in vivo study, an 
animal subcutaneous model was used to assess the anti-tumor effect of the composite film 
on rat C6 glioma. Treatments were initiated by implanting the composite films onto the 
tumor. The tumor growth was monitored by measuring tumor volume using a caliper, an 
ultrasound machine, and an optical imaging system.  
 
 The chitosan/ellagic acid composite films exhibited increase in amide and ester 
linkages, diffraction peaks of the crystallized ellagic acid, enhanced surface roughness, 
and hydrophilicity with increasing concentration of ellagic acid. The composite films 
degraded enzymatically, indicated by at least a 5 times higher concentration of free amino 
groups in the incubation medium at 3 weeks compared with 1 day. They also displayed a 
sustained slow release of ellagic acid in vitro for 3 weeks incubation. Anti-cancer activity 
of the composite films was ellagic acid concentration dependent by inducing apoptosis of 
cancer cells and suppressing angiogenesis. Significant inhibitory effect (p<0.05) was 
found in the composite films containing 0.5% (w/v) of ellagic acid or higher compared 
with other groups. Study of a rat C6 glioma model demonstrated that the composite film 
(Ch/EA20) significantly inhibited tumor growth compared with control groups in vivo. 
Tumor volume increase in Ch/EA20 group was 9 times lower than that in control groups 
at 3 weeks observation by measuring a caliper. No severe weight loss (>10% wt.) was 
observed from all groups. Histology observation indicated no evidence of severe toxicity 
surrounding the composite films. The high efficacy and low toxicity of the composite 
film was attributed to the slow release and localized effect of ellagic acid.  
 
 In order to further improve the delivery method and efficacy, chitosan based 
 vi 
injectable hydrogel was developed for a local administration of ellagic acid to avoid 
surgical complications. Studies of the chitosan gel were performed with regard to 
chemical structure, surface morphology, viscoelasticity, release profile, and degradation 
behavior. Biocompatibility and anti-cancer activity on chitosan gel delivery system were 
examined. The results showed that the injectable chitosan liquid formulation underwent 
thermal gelation at body temperature via hydrophobic interactions using β-
glycerophosphate salt (β-GP). Sol-gel transition was dependent on final pH values of the 
chitosan/β-GP solution and temperature. Dialysis of chitosan solution reduced the β-GP 
needed to reach pH 7.2, resulting in 4 times higher cell viability than undialyzed chitosan 
gel at 3 days culture. This result indicates improved biocompatibility of the delivery 
system. The chitosan/β-GP gels were enzymatically degradable for 3 weeks incubation 
and inhibited cancer cell growth in vitro in an ellagic acid concentration dependent 
manner. The significant inhibitory effect (p<0.05) was found in the gel containing 1% 
(w/v) of ellagic acid compared with other groups. Viability of U87 cells and C6 cells 
cultured on chitosan gels containing 1% (w/v) of ellagic acid were lower than the same 
cells on chitosan gels at 3 days incubation by 3.8 times and 6.5 times, respectively. 
 
 This research has demonstrated that the chitosan/ellagic acid delivery system is a 
promising biomaterial for a local cancer treatment. This study has also suggested a 
potential strategy with higher efficacy and lower toxicity to treat tumors by the 
combination of naturally based biopolymers such as chitosan and phenolic compounds 
such as ellagic acid. This study provides some rationale for further investigation of 
implantable polymeric delivery system. 
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CHAPTER 1. INTRODUCTION 
 
 
 Despite significant progress in anti-cancer therapy, cancer is still the second 
leading cause of death after heart disease and responsible for one of four deaths in the 
United States [ACS 2008, Jain 2001]. Approximately 1,437,180 new cases of invasive 
cancer in the United States are diagnosed and nearly 565,650 died of the cancer in 2008 
[ACS 2008]. Especially, brain cancer is the leading cause of cancer-related death in 
patients younger than age 35 [ACS 2008]. Recently, local drug delivery system has been 
considered as a practical approach for cancer treatment compared with conventional 
chemotherapy. In conventional chemotherapy, cancer drugs are nonspecifically 
distributed, thus leading to a rapid loss of the efficacy and potential systemic toxicity into 
the body. In addition, for brain cancer, the blood-brain-barrier limits the access of 
therapeutic agents to brain tumor [Graham 2004, Wang 2002]. However, local delivery 
system has the potential to control drug release, thereby increasing efficacy and safety.   
 
 The common strategy of local delivery system is increasing therapeutic dose to 
the tumor site while reducing drug exposure to normal tissue [Groothuis 2000, Jain 2001, 
Moses 2003]. In particular, polymeric delivery system is implantable at a local site and 
biodegradable after a therapeutic span. A drug is incorporated into a polymeric device and 
released in a controlled manner. This delivery system can be optimized using 
characteristics of drugs and polymers in terms of solubility, degradation, and 
drug/polymer interactions. 
 
 In this regard, this section provides information of polymeric delivery systems 
regarding controlled drug release and degradation. In addition, ellagic acid, a naturally 
occurring phenolic compound, is introduced regarding its biological properties and anti-
cancer mechanism. It is of interest to explore the feasibility of use of a dietary substance 
as a promising strategy for cancer treatment. Further, the study of the biological effects of 
chitosan/ellagic acid composite materials helps to establish a platform for a local 
chemotherapy. 
 
 
1.1 Local Drug Delivery Systems 
 
 A drug delivery system is a device to maintain effective drug levels in the body 
for a desired time period. In the conventional delivery system, drug is frequently 
administered in the form of liquid or powder, causing problems associated with systemic 
toxicity. Local delivery system is designed for a steady release of drug at a specific site, 
thus remaining drug levels between maximal toxicity and minimal inefficacy [Dash 1998, 
Park 1996]. Current technical advances in drug delivery have enabled the drug to be 
incorporated into a variety of devices such as osmotic pump, transdermal patch, lipsomal 
encapsulation, and implantation [Dash 1998, Moses 2003]. Table 1.1 summarizes 
currently available local drug delivery systems and their applications. These delivery 
systems have been explored to optimize the therapeutic efficacy of drugs, bio-molecules, 
and growth factors for long term delivery regarding stability and safety.  
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Table 1.1 Representative local drug delivery systems and their characteristics currently in 
use.  
 
 
 
 
 
 
Delivery method  Material type Characteristics  
External portable 
infusion Osmotic mini pump 
Direct intratumoral treatment 
Continuous and controlled 
delivery 
Scheduled administration 
Transdermal 
delivery 
Adhesive & 
Multi-layer patch 
Diffusion through skin 
Controlled release  
No pains 
Intravenous infusion 
(I.V.) 
Liposomal delivery 
Prolonged drug circulation  
(long circulation lifetime) 
High drug capacity 
Biodegradable and low toxicity 
Pegylated delivery 
Prolonged drug circulation  
Stable and non-immunogenic 
device 
Site specific delivery 
Polymeric 
implantation 
Micro-, nano-sphere Localized and sustained release  Biodegradable implant  
Wafer Localized and sustained release  Biodegradable implant 
Injectable gel 
Localized and sustained release  
Biodegradable implant 
Non surgical delivery  
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 Osmotic pump has been employed to continuously administer a drug on a 
schedule and maintain a long term control of local diseases, resulting in higher 
therapeutic efficacy [Drixler 2000, Giussani 2003, Kisker 2001]. It is directly implanted 
at targeted local area, and the drug is frequently introduced with low dose and remains a 
sustained circulating level. ALZET mini pump has been used to avoid the blood-brain 
barrier (BBB) of brain and directly administer a drug to the central nervous system 
[Giussani 2003].  
 
 Transdermal devices have been designed for a continuously delivery of a drug 
through the skin into the systemic circulation in a time and dose dependent manner 
[Isoniemi 2001, Tonnesen 1999]. A drug is loaded in the polymeric patches and directly 
released into the bloodstream via difference in drug concentrations between the device 
and the blood flow. This system consists of liners, adherents, drug reservoirs, and drug 
release membrane. For instance, transdermal patches are used for patients with 
pulmonary disease and cardiovascular disease associated with increases in heart rate and 
blood pressure [Tonnesen 1999]. This system induces controlled release of the drug 
without pains.  
 
 Using a lipsomal encapsulation technique, therapeutic agents such as drugs, 
proteins, and genes are encapsulated into liposomes and circulate into the bloodstream 
through diffusion and liposomal degradation [Maurer 2001]. The ability to encapsulate 
the therapeutic agents is dependent on physicochemical properties of liposomes such as 
polarity, charge, and size. This system can prolong circulation time by reducing volume 
of drug distribution within the bloodstream and increase drug carrying capacity compared 
with a simple intravenous injection [Burstein 1999, Maurer 2001]. This results in reduced 
toxic side effects on normal tissues and increased efficacy of therapeutic agents. For 
example [Lyass 2000, Marina 2002], Doxil is a different form of doxorubicin which is 
used for cancer treatments. Doxorubicin interacts with DNA and inhibits nucleic acid 
synthesis. Doxil is composed of a liposome and a layer of methoxypolyethylene glycol 
(MPEG). MPEG is used to prevent the crosslinking and polymerization of molecules, 
resulting in increased biocompatibility and reducing immune response [Rose 2005]. This 
pegylation can protect liposomes from detection and destruction by monocytes and 
macrophages in the liver and spleen, resulting in extended therapeutic span [Maurer 
2001]. 
 
 The major problems in the conventional chemotherapy are attributed to an initial 
burst effect of drugs, leading to a rapid loss of the efficacy and harmful side effects into 
the body. In this regard, implantable polymeric delivery system has gained a lot of 
attention for controlled steady release, thus extending therapeutic span and minimizing 
side effects [Dash 1998, Park 1996]. Drugs are physically embedded or chemically 
conjugated in polymeric devices such as gels, beads, or wafers.  
 
 For instance, gliadel® wafer has been used to deliver carmustine (BCNU) into the 
surgical cavity for brain cancer treatment [Olivi 2003, Perry 2005]. It consists of 
carboxyphenoxypropane (CPP) and sebacic acid (SA) in the polymer. The carmustine is 
distributed into the copolymer and functions as an alkylating agent, which treats brain 
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cancer including glioma and glioblastoma multiforme [Brem 2001].When the anhydride 
bonds in the copolymer degrade, carmustine is released from the gliadel wafer and 
diffuses into the adjacent brain tissue. During the biodegradation of the gliadel wafer, 
carboxyphenoxypropane is eliminated by the kidney while sebacic acid is metabolized by 
the liver [Brem 2001, Hanes 1996, Katti 2002].  
 
 As an example of implantable devices, poly (lactic acid-co-glycolic acid) 
(PLGA) microspheres have been studied to deliver 5-fluorouracil (5-FU), which is a 
hydrophilic and antimetabolite drug used for cancer treatment [Menei 1999, 2004]. After 
surgical resection of the tumor, 5-fluorouracil (5-FU) loaded PLGA microspheres are 
implanted intracranially to extend therapeutic duration and to avoid systemic toxicity 
around brain tissue. The implantable microspheres have been shown to be biocompatible 
and biodegradable. 
 
 
1.2 Implantable Polymeric Delivery System 
 
 One of major considerations in development of local delivery systems is 
biocompatibility. Polymeric systems are implantable and sustained contact with the local 
tissues, thus, polymers and degradable products should be non-toxic. They may be 
synthetic or natural, and biodegradable or non-biodegradable. In particular, the 
biodegradable delivery systems alleviate the need for surgical removal of the implant, 
thereby increasing patient acceptance and compliance [Gunatillake 2003]. They are 
disintegrated by hydrolysis of the polymer chains into biologically acceptable polymer 
products over time. The biodegradable polymers have hydrolysable linkages such as ester, 
amide, anhydride, orthoester, urea, carbonate, and urethane in their backbone 
[Gunatillake 2003]. They are absorbed or excreted from the body via normal metabolic 
pathways without any complications. The biodegradation of the polymers is attributed to 
some factors such as polymer structure, composition, morphology, surface structure, 
molecular weight, shape, size, and etc [Dash 1998, Jain 2000]. Drug release of 
biodegradable systems is governed by diffusion, initial drug loading, drug/polymer 
interactions, drug solubility, and polymer degradation [Gunatillake 2003]. In contrast, 
non-biodegradable polymeric systems need a minor surgery to remove the implant. The 
drug release is achieved by diffusion via pores in the polymer matrix or between polymer 
chains [Dash 1998].  
 
 
1.2.1 Biodegradable Polymers 
 
 Biodegradable polymers such as polyesters, polyamides, polyanhydrides, 
polyorthoesters, polycarbonates and polyurethanes have been most extensively studied 
for controlled drug release. Table 1.2 summarizes the structure of key biodegradable 
polymers used in drug delivery systems. Among biodegradable polyesters, poly(lactic 
acid) (PLA), poly(glycolic acid) (PGA), or their copolymers poly(lactic-co-glycolic acid) 
(PLGA) have been extensively studied in the forms of film, micro or nanosphere, and 
hydrogel [Fialho 2005, Jeong 2000, Yamaguchi 2002].  
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Table 1.2 Structural classification of biodegradable polymers used in drug delivery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymer class  Structure of repeating unit  
Polyesters 
 
 
Polyanhydrides 
 
 
Polyorthoesters 
 
 
Polycarbonates 
 
 
Polyamides 
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 Drugs are released by the cleavage of the polymeric chains via hydrolytic 
degradation or enzymatic degradation while polymers breakdown into their monomers 
and metabolized under physiological conditions [Gunatillake 2003]. In the copolymers 
(PLGA), the molecular weight and the ratio of PLA and PGA monomers play an 
important role in controlling the drug release [Jain 2000]. The lower molecular weight 
polymer has, the faster it degrades, and copolymer degrades faster than the 
homopolymers. 
 
 Polyanhydrides degrade fast in an aqueous environment by hydrolysis of 
anhydride linkages. They have unique degradation properties for the controlled drug 
release, which is mostly affected by their surface degradation [Gopferich 2002]. The most 
well studied polyanhydrides, for example, is poly [1,3-bis (carboxyphenoxy) propane-co-
sebacic-acid] p(CPP-SA) used for patients with brain tumors [Dang 1996, Katti 2002]. 
Unlike poly (lactic-co-glycolic acid) (PLGA), which is degraded by bulk erosion, 
polyanhydride is degraded by surface erosion. The surface erosion occurs only at the 
surface of the polymer while the bulk erosion includes entire polymers. The physical 
properties of p(CPP-SA) can be altered by different ratio of monomers (CPP:SA), 
influencing polymer degradation rate thereby controlling drug release behavior [Dang 
1996, Gopferich 2002]. The polyanhydride polymers provide several advantages such as 
constant release (zero order kinetics) over a long period of time, controllable release rate, 
and degradation after therapeutic span [Katti 2002]. 
 
 Polyorthoesters are also biodegradable polymers by surface erosion and 
fabricated into wafers, microspheres, injectable semi-solid materials. The polymer 
erosion occurs by hydrolysis mostly in the outer layers of the polymer matrix, and the 
drug is released concomitantly [Heller 2002]. The drug release rate is proportional to 
initial drug loading rate. The local acidity attributed to polymer degradation can be 
controlled and a neutral pH inside polymeric device remains because hydrolysis products 
generally diffuse away from the device [Heller 2000, Zignani 2000]. In others, tyrosine-
derived polycarbonates and polyutethanes have been investigated as biodegradable 
polymers [Tangpasuthadol 2000]. Tyrosine-derived polycarbonates contain three 
hydrolysable bonds such as amide, ester, and carbonate and yield alcohols and carbon 
dioxide after hydrolysis of the carbonate groups. Polyurethanes have been used in a broad 
range of biomedical applications due to their good mechanical properties and 
biocompatibility [Simmons 2008]. However, the toxicity generated from degradation 
products should be considered. 
 
 There are many types of non-degradable polymers. They have been studied for 
controlled drug release applications, including poly [ethylene-co-(vinyl acetate)] (EVAc), 
poly(methyl methacrylate) (PMMA), poly(ethylene glycol) (PEG), Poly (N-isopropyl 
acrylamide) (PNIPAAm), and poly(dimethylsiloxane) (PDMS) [Liu 2005, Park 1996, 
Zhang 2003]. Slow diffusion via the polymeric delivery system provides sustained drug 
release from the delivery system [Dash 1998]. However, a major disadvantage of these 
delivery systems is a need for surgical removal of the implants after the completion of 
therapy. In order to approach effective sustained release from, the polymer networks, 
interactions between drugs and polymer molecules are also critical. In this regard, non-
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biodegradable polymers are not preferred for large molecular weight drugs and 
biomolecules, and they may induce any risks related to inflammation and long term 
complications. 
 
 
1.2.2 Natural Chitosan Polymer 
 
 Natural polymers such as polysaccharides, collagen, albumin, and cellulose 
derivatives are also employed for drug delivery because they are non-toxic, 
biocompatible, and biodegradable. Most natural polymers are degraded by enzymatic 
hydrolysis. Recently, chitosan has been of great interest among polysaccharides due to 
the presence of nitrogen group, giving rise to chemical reactions with other chemicals. It 
has been studied for a variety of biomedical applications, including wound healing, tissue 
regeneration, and drug/gene delivery [Kumar 2000, Pillai 2009].  
 
 Chitosan is the fully or partially N-deacetylated derivative of chitin, which is the 
most abundant natural amino polysaccharide, obtained from shellfish sources such as 
crab and shrimp [Kumar 2000, Pillai 2009]. Chitosan and chitin have structural similarity 
to cellulose in plants, and they are copolymers consisting of N-acetyl-glucosamine and N-
glucosamine units [Chatelet 2001]. Chitin contains higher than 50% of N-acetyl-
glucosamine units and has limited solubility in common solvents and chemically less 
reactive (Figure 1.1a). In contrast, chitosan contains higher proportion of N-glucosamine 
units (above 50 %) in the polymer than chitin. It is soluble in dilute acids and has better 
reactivity for chemical reactions [Khan 2002].  
 
 Unlike the other polysaccharides such as cellulose and dextran, chitosan is a 
positively charged polysaccharide in acidic solvent along with its molecules. Amine 
groups (NH2) of chitosan are protonated (NH3+) in an acidic solution, presenting an 
important characteristic of chitosan. Several parameters responsible for free amine groups 
of chitosan include the degree of deacetylation (DDA), molecular weight, and 
environmental factors such as pH, solvent, temperature, and etc [Wang 2006]. Increase in 
the degree of deacetylation (DDA) significantly lowers the protonation constants pKa, 
influencing hydrophobic interactions and hydrogen bondings between chitosan molecules 
[Wang 2006]. Increase in molecular weight of chitosan also lowers the protonation 
constants pKa.  
 
 Chitosan is hydrolyzed by different enzymes such as chitosanase and lysozyme 
[Muzzarelli 1997, Pangburn 1982, Tomihata 1997]. The chitosanase is completely absent 
in mammals but lysozyme is mainly responsible for the degradation of chitosan in human 
body. Lysozyme is present in tissues, saliva, blood, and tears, and it is used by phagocytic 
cells during the inflammatory response [Pillai 2009]. Lysozyme hydrolyses glycosidic 
bonds of chitosan molecules, but it is less active on chitosans with higher DDA 
[Pangburn 1982, Stokke 1995].  
 
 The hydrolysis reaction of the lysozyme includes proton (H+) transfer from a 
carboxyl group of a glutamic acid (Glu-35) to the substrate and then a hydroxyl group of  
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                                   (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
                              
 
Figure 1.1 Schematic drawings of (a) repeating unit in chitin and chitosan and (b) the 
enzymatic hydrolysis at glycosidic bonds of chitosan molecules. R is acetyl (COCH3) or 
hydrogen (H) group. Chitin has more than 50% of acetyl groups while chitosan has more 
than 50% of hydrogen groups in their backbone. Lysozyme attacks the glycosidic bond 
by donating a proton and a water molecule reacts with a carbon atom in an amino sugar 
group, leading to hydrolysis.  
 
 
Sources:  
Muzzarelli R. Human enzymatic activities related to the therapeutic administration of 
chitin derivatives. Cellular and Molecular Life Sciences. 1997;53:131-140. 
Pillai CKS, Paul W, Sharma CP. Chitin and chitosan polymers: Chemistry, solubility and 
fiber formation. Progress in Polymer Science 2009;34:641-678. 
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a water molecule is added to a carbon atom in an amino sugar group [Muzzarelli 1997]. 
As shown in Figure 1.1b, chitosan is biodegradable into amino sugar groups via the 
metabolic pathways of glycosaminoglycans and glycoproteins [Chatelet 2001]. 
Degradation rate of chitosan polymer can be controlled using the degree of deacetylation 
(DDA) and molecular weight which are considered as critical parameters influencing 
physicochemical properties of chitosan [Li 2007, Wang 2006].  
 
 Chitosan has beneficial properties such as biocompatibility, biodegradability, 
non-toxicity, low immunogenicity, anti-bacterial, anti-fungal, and anti-viral activity 
[Kumar 2000]. Recently, chitosan is considered as a promising biodegradable carrier for 
controlled drug release with respect to safety and efficacy of drug therapy [Ravi- Kumar 
2006]. Its positively charged molecules interact with negatively charged therapeutic 
agents and biomolecules. Generally, drugs are chemically attached or dispersed into the 
chitosan matrix and released via slow and controllable diffusion or biodegradation [Freier 
2005, Hong 2007, Ren 2005].Chitosan has been fabricated in a variety of form such as 
film, sponge, hydrogel, and beads. Chitosan itself has an ability to form a gel and can be 
modified via its amino and hydroxyl groups [Wang 2006]. Chitosan has been 
incorporated with the other polymers or crosslinking reagents via chemical modification. 
Chemical modifications of chitosan have been studied to improve its solubility and 
extend applications via etherification, esterification, cross-linking, and graft 
copolymerization [Gorochovceva 2004, Jayakumar 2005, Sashiwa 2004, Yoshifuji 2006]. 
These modifications influence physicochemical and biological properties of chitosan as a 
carrier for various therapeutic agents.  
 
 
1.3 Dietary Polyphenols 
 
 The recent interest in the biological activity of the phenolic compounds is a result 
of the potential health benefits of dietary constituents. It is well known that consumption 
of polyphenol-rich foods or beverages can prevent various human diseases. The 
polyphenols obtained from fruits, vegetables, and herbs are protective against 
cardiovascular disease, inflammation and cancer [Stoclet 2004]. The emerging evidence 
showed their drug-like effects on human body in many ways, but low side effects 
compared with pharmaceutical drugs. Health benefits of several polyphenols have been 
examined in their extract forms [Scalbert 2000]. The chemical structure of polyphenols 
influences bioavailability, antioxidant activity, and interactions with cells or enzymes 
[Han 2007, Scalbert 2000, Williamson 2000]. This review summarizes the current 
understanding of the biological activity of polyphenols and their feasibility for a local 
drug delivery.  
 
 
1.3.1 Chemical Structure 
  
 The dietary phenolic compounds contain the most abundant antioxidants in 
human diets, contributing to anti-carcinogenic or cardio-protective action [Han 2007, 
Stoclet 2004]. The phenolic compounds, plant secondary metabolites, contain a number 
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of phenolic hydroxyl groups, inducing the antioxidant activity [Rice-Evans 1996]. They 
can be subdivided into several groups according to their structural differences. More than 
8,000 different phenolic structures have been studied and broadly categorized into 10 
classes [Scalbert 2000]. But, only a limited number of phenolic substances have been 
used for human diets.  
 
 The two main categories are non-flavonoids (e.g. phenolic acids, stilbenes) and 
flavonoids as shown in Figure 1.2 [Scalbert 2000]. The phenolic compounds are often 
attached to sugars (glycosides) and most of them are water soluble. The phenolic acids 
have simple molecular structures derived from hydroxybenzoic acids such as ellagic acid, 
caffeic acid, gallic acid, and etc [Stoclet 2004]. The flavonoids are the most abundant and 
account for two thirds of the total phenolic compounds [Scalbert 2000]. They can be 
divided into several classes, including flavonols, flavones, isoflavones, anthocyanins, 
flavanols, and etc [Han 2007]. Basically, they have two phenols connected by a pyran 
carbon ring structure. Individual differences of phenolic substances are attributed to the 
variation of hydroxyl groups, oxygens, sugars, and methyl groups [Rice-Evans 1996].  
  
 These structural diversities occur via hydroxylation of the phenolic rings, 
glycosylation, and acylation [Scalbert 2000, Han 2007]. The structural diversity 
influences absorption, distribution, bioavailability, and biological properties of phenolic 
compounds. The antioxidant activity is dependent on the relative positions of the 
hydroxyl groups in the ring structures [Rice-Evans 1996]. 
 
 
1.3.2 Biological Properties 
  
 A wide range of biological properties of the phenolic compounds have been 
extensively reviewed. Many scientists have investigated the importance of the use of 
fruits and vegetables for health care to verify their therapeutic effects. Many studies 
demonstrated the phenolic compounds have anti-carcinogenic, anti-inflammatory, anti-
bacterial, anti-allergic, and anti-viral properties [Han 2007, Loo 2003, Scalbert 2000]. In 
addition, the dietary phenolic products show the protective effect against cardiovascular 
risk by inhibiting the angiogenic process and preventing the growth of endothelial and 
vascular smooth muscle cells [Stoclet 2004]. 
 
 The main action of phenolic compounds is direct control of the oxidation stress 
by modulating the free radicals in biological systems [Loo 2003, Rahman 2006]. 
Oxidation stress may occur when antioxidant defense systems fail to manage the 
production of free radicals. The imbalance between antioxidants and free radicals results 
in oxidative stress, leading to cellular damage. The free radicals are highly reactive and a 
main cause of accelerated aging, degenerative diseases, and abnormal cell growth [Han 
2007]. Many dietary phenolic substances have been investigated to reduce the level of 
free radical via a number of potential antioxidative mechanisms. They have been studied 
concerning antioxidant capacity and regulation of cellular activity. The phenolic 
compounds can act as antioxidants by breaking the free radical chain reaction [Scalbert 
2000]. Antioxidants protect biological system against the reactive oxygen species (ROS) 
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Figure 1.2 Major chemical structures of dietary phenolic substances. The two main 
categories are (a) non-flavonoids including gallic acid, ellagic acid and caffeic acid; (b) 
flavonoids including quercetin and anthocyanins. The phenolic substances vary 
structurally with substituent groups and linkages. Main structural difference is presence 
of a pyran carbon ring structure which connects two phenols in flavonoids. 
 
 
Sources: 
Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and 
therapy of cancer. Biochemical Pharmacology 2006;71:1397-1421. 
Han X, Shen T, Lou H. Dietary polyphenols and their biological significance. 
International Journal of Molecular Sciences 2007;8:950-988. 
Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. The Journal 
of Nutrition 2000;130:2073S-2085S. 
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such as oxygen, superoxide, peroxyl radicals, and hydroxyl radicals [Loo 2003, Rahman 
2006]. 
 
 The antioxidant activities of the phenolic compounds depend on their ability to 
scavenge free radicals and chelate metal ions [Loo 2003, Rahman 2006, Scalbert 2000]. 
The molecular structure of phenolic compounds highly influences antioxidant capacity. 
The hydroxyl groups associated with phenolic rings play an important role in scavenging 
free electrons, resulting in decease in oxidative reactions of biological molecules [Loo 
2003, Rice-Evans 1996]. Phenolic compounds chelate the metal ions such as copper or 
iron in the oxidation systems [Rice-Evans 1996]. Such chelation of catalytic metal ions 
can prevent the formation of the reactive hydroxyl radicals. Therefore, biological 
activities of the phenolic compounds correspond to specific characteristics including 
metal reducing potential, chelating behavior, pH, bioavailability, and solubility [Rahman 
2006, Rice-Evans 1996, Scalbert 2000]. However, the relationship between biological 
activities of the phenolic compounds and their antioxidant properties needs further study.  
 
 The phenolic compounds also take part in modulating the activation of protein, 
enzymes and transcription factors in the metabolic pathways. Several studies 
demonstrated that phenolic compounds have structural similarities with biological 
molecules in size, molecular weight, and partial hydrophobicity [Han 2007, Loo 2003]. In 
this regard, phenolic compounds have an ability to inhibit the development of 
degenerative diseases and limit the activation of carcinogens.  
 
 
1.3.3 Bioavailability 
 
 There is limited bioavailability of the phenolic compounds due to the poor 
absorption in the body and high metabolism in human [Rahman 2006, Scalbert 2000]. 
The bioavailability of phenolic compounds has been investigated by measuring their 
concentrations in plasma and urine after the ingestion [Scalbert 2000]. Some studies have 
demonstrated that the absorption of the phenolic compounds after the ingestion depends 
on the amounts consumed and their bioavailability [Scalbert 2000]. Most phenolic 
compounds containing glycosides and ester groups are hydrolyzed to the free aglycone by 
intestinal enzymes or colonic microflora before they are absorbed [Manach 2003, 
Spencer 1999, Scalbert 2000]. During a process of absorption, phenolic compounds are 
conjugated by methylation, sulfation, and glucuronidation in the small intestine and liver 
[Rice-Evans 1996, Spencer 1999]. This process is controlled by distribution of specific 
enzymes involved in phenolic metabolism. The conjugation mechanisms are highly 
effective to reduce concentration of aglycones in blood after consumption of dietary 
phenolic compound [Stoclet 2004]. Unlike enzymes in human tissues, colonic microflora 
produces more simple phenolic compounds, such as phenolic acids [Manach 2003, 
Scalbert 2000]. 
 
 The chemical structure of phenolic compounds is an important factor 
contributing to the bioavailability. It influences the rate and extent of intestinal absorption 
and metabolites in the plasma [Manach 2003, Spencer 1999]. Some phenolic compounds, 
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such as flavonoids including flavonols, isoflavones, flavones and anthocyanins, are 
glycosylated [Spencer 1999]. This glycosylation influences chemical, physical and 
biological properties of the phenolic compound. The majority of sugars connected to 
phenolic rings are glucose or rhamnose, and their possible positions are various. The 
sugars are removed by glycosidases in the first step of phenolic metabolism [Day 2001]. 
The molecular weight also affects the absorption rate of phenolic compounds. 
Proanthocyanidins are the least well absorbable phenolic compound in the small intestine 
due to their large molecular weight [Scalbert 2000]. The hydrophilicity of glycosylated 
phenols influences passive diffusion across the small intestine [Rice-Evans 1996]. The 
dosage difference also affects the main site of metabolism. High dosages are metabolized 
mostly in the liver while low dosages are metabolized by the intestinal mucosa [Manach 
2003, Spencer 1999]. In addition, phenolic compounds can penetrate tissues but they are 
less accumulative on specific target tissue [Spencer 1999]. Many studies have focused on 
verifying biological properties of phenolic compounds contributing to human health. 
However, there often exist inconsistent results between the studies of the in vitro and in 
vivo, mainly due to the limited bioavailability of phenolic compounds [Han 2007].  
 
 
1.4 Ellagic Acid 
 
 Ellagic acid is one of extensively studied phenolic compounds. It presents in 
various fruits and nuts such as raspberries, strawberries, blackberries, grapes, 
pomegranates, walnuts, pecans, and barks [Mullen 2003, Vekiari 2008]. The high 
therapeutic levels of ellagic acid have been obtained from red raspberries, strawberries, 
and pomegranates compared to other sources [Pinto 2008]. In recent years, increasing 
evidence has shown that the ellagic acid has the antioxidant and anti-cancer properties 
against cancer [Pinto 2008, Vekiari 2008]. It is safe, low-priced, and supplied as a dietary 
food. Ellagic acid has an ability to induce apoptotic cell death of cancers in cervical, skin, 
breast, lung, esophageal, brain, colon, liver, and etc [Edderkaoui 2008, Losso 2004, 
Narayanan 1999, Labrecque 2005]. It also inhibits formation and growth of cancer cells 
by influencing cell cycle arrest and preventing destruction of the p53 gene by cancer cells 
[Dixit 1986, Edderkaoui 2008, Khan 2007, Mertens-Talcott 2003, 2005]. It functions as a 
scavenger by binding cancer-causing chemicals and inactivating them [Barch 1996, 
Scalbert 2000]. Some researches indicated that ellagic acid also contains anti-
inflammatory, anti-bacterial, and anti-viral properties [Losso 2004, Whitley 2003]. 
 
 Ellagic acid itself is not naturally present in plants, but found in the form of 
ellagic acid glycosides or hydrolyzable ellagitannins as shown in Figure 1.3 [Feldman 
2005, Mullen 2003]. The ellagic acid glycosides are various according to their chemical 
structures. Their common structures include a single sugar group joined to a hydroxyl 
group at 4 position of ellagic acid. Ellagitannins contain one or more 
hexahydroxydiphenoyl groups (HHDP) which are conjugated to sugar groups or glucose 
groups [Feldman 2005]. Ellagitannins are easily converted into the ellagic acid via 
hexahydroxydiphenoyl groups (HHDP) after breaking ester linkages between glucose and 
ellagic acid by hydrolysis. The types of ellagitannins are various according to the number 
of HHDP groups, the location of ester groups, and the conformation of the glucose ring  
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Figure 1.3 Ellagic acid and its derivatives. Ellagitannins are hydrolyzed to 
hexahydroxydiphenoyl groups (HHDP) which are spontaneously converted to ellagic acid. 
Different ellagic acid glycosides are hydrolyzed to ellagic acid.  
 
 
Sources: 
Feldman KS. Recent progress in ellagitannin chemistry. Phytochemistry 2005 ;66 :1984-
2000. 
Mullen W, Yokota T, Lean ME, Crozier A. Analysis of ellagitannins and conjugates of 
ellagic acid and quercetin in raspberry fruits by LC-MSn. Phytochemistry. 2003;64:617-
624. 
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[Mullen 2003, Vekiari 2008]. Ellagic acid is generally produced in a highly concentrated 
form from seeds. Its seeds are processed into the flour with regard to maximum 
bioavailability and convertability into ellagic acid [Vekiari 2008].  
 
 Ellagic acid is a complex molecule containing four hydroxyl groups and two 
lactone groups. It has been suggested that different portions of the ellagic acid such as 3-
hydroxyl and 4-hydroxyl groups influence different anti-cancer activities [Barch 1996, 
Feldman 2005]. Lactone groups of ellagic acid are also known to be essential to induce 
anti-cancer activity [Barch 1996]. One ellagic acid molecule looks like a combination of 
two gallic acid molecules. Thus, the carboxylic acid joined with a phenolic ring of gallic 
acid possibly functions as the lactone groups in ellagic acid [Barch 1996]. In this regard, 
during the processing, the structural change of ellagic acid may significantly influence its 
solubility and bioavailability as well as anti-carcinogenic activities [Dixit 1986, Rice-
Evans 1996]. Studies of bioavailability showed that ellagic acid was found in the stomach 
and from the action of the gut microflora after consumption [Scalbert 2000, Seeram 2004, 
2006]. However, ellagic acid is poorly absorbed and present in low concentrations, 
leading to the limited bioavailability [Scalbert 2000, Seeram 2006]. 
 
 
1.5 Anti-Cancer Mechanisms 
 
 
1.5.1 Apoptosis 
 
 Apoptosis is a form of programmed cell death and a highly regulated process to 
remove damaged cells [Bai 2006]. Apoptosis represents a set of morphologic changes, 
including chromatin condensation, nuclear fragmentation, membrane blebbing and cell 
shrinkage [Khan 2007]. Unlike necrosis causing inflammatory response to surrounding 
tissues, apoptosis maintains the contents of the cell within the cell membrane when it is 
degraded. Subsequently, the apoptotic cells are phagocytosed by macrophages without 
inducing inflammation [Bai 2006]. Induction of apoptosis is a preferential target for 
cancer chemotherapy. Many studies have shown that dietary substances have an ability to 
induce apoptosis of cancer cells [Ahmad 2001, Gopalakrishna 2002, Lazze 2004, Loo 
2003, Losso 2004, Mertens-Talcott 2003, 2005, Rahman 2006, Schuler 2000]. 
 
 Numerous studies have suggested that the phenolic compounds inhibit the 
proliferation of cancer cells by inducing cell cycle arrest or apoptosis. This is mainly 
because of its ability to scavenge reactive oxygen species (ROS) such as hydrogen 
peroxide (H2O2) [Loo 2003, Rahman 2006, Sun 1996]. H2O2 is a destructive toxic 
molecule and easily converted to hydroxyl radicals (HO.) which cause oxidative damages. 
It also acts as an important signaling molecule in the mitogen-activated protein kinase 
(MAPKs) pathways [Loo 2003, Rahman 2006, Sun 1996]. The MAPK cascades include 
extracellular signal-related protein kinases (ERKs), c-Jun N-terminal kinases (JNKs), and 
p38 kinases [Loo 2003]. The ERK pathway is activated by growth factors and promotes 
cell growth and survival. The JNK and p38 kinases are activated in response to oxidative 
stress and involved in apoptosis. MAPKs activate redox-sensitive transcription factors 
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such as nuclear factor-kappa B (NF-kB) and activator protein-1 (AP-1), promoting the 
survival and proliferation of cancer cells [Edderkaoui 2008, Lee 2003, Loo 2003, 
Mertens-Talcott 2005, Rahman 2006, Sun 1996]. In this manner, the phenolic compounds 
can induce apoptosis by scavenging the excessive free radicals, thereby blocking MAPK 
signaling pathway.  
  
 The phenolic compounds can also induce apoptotic process via the intrinsic 
mitochondrial pathway [Khan 2007]. The intrinsic apoptotic pathway involves the 
expression of regulatory proteins such as increased Bax, the release of cytochrome c, and 
increased caspase activity, as well as decreased Bcl-2 and Bcl-XL [Larrosa 2006, Lee 
2003, Schuler 2000]. The actions of pro-apoptotic and anti-apoptotic proteins are 
frequently associated with the activation of p53. The transcription factor p53 is an 
important key protein known as a tumor suppressor, regulating cell cycle and apoptosis. 
In cancer cells, the function of p53 can be lost by various mechanisms such as mutations 
[Bai 2006]. In normal cells, the p53 is usually inactive and sustained at low level by a 
continuous degradation. It is bound to the protein MDM2, which prevents the function of 
p53 and induces the degradation by transporting from the nucleus to the cytosol 
[Aggarwal 2006, Bai 2006]. In response to DNA damages, the p53 is activated by 
phosphorylation at the N-terminal region and accumulated in the nucleus [Bai 2006]. The 
representative target genes of p53 are p21Waf1/Cip1, growth arrest and DNA-damage 
inducible protein 45 (Gadd45) and the Bcl-2 family[Ahmad 2001, Bai 2006, Khan 2007]. 
They are mostly involved in cellular responses such as cell cycle arrest, DNA repair, 
apoptosis and senescence.  
 
 The intrinsic pathway is triggered by the signal factors from mitochondria in 
response to cellular stresses such as DNA damage, heat shock, hypoxia, and oncogene 
overexpression [Aggarwal 2006, Bai 2006]. The pro-apoptotic Bcl-2 family proteins are 
involved in this pathway and induce caspase activity from the mitochondria. The pro-
apoptotic proteins such as PUMA, NOXA, and BID attach to the outer mitochondrial 
membrane for the release of the internal content [Aggarwal 2006, Khan 2007]. In 
response to apoptotic signaling, BID activates BAX and inserts it into the outer 
mitochondrial membrane. The activated BAX forms an oligomeric pore, releasing 
cytochrome c and other pro-apoptotic factors from the mitochondria. BAK is another pro-
apoptotic protein inside the mitochondria, also induces the release of cytochrome c, 
leading to the activation of caspases. However, the anti-apoptotic Bcl-2 proteins such as 
Bcl-2 itself and BCL-XL, also bind to BID and inhibit the activation of BAX or BAK 
[Bai 2006, Khan 2007]. After being released from the mitochondria, cytochrome c makes 
a complex structure with adenosine triphosphate (ATP) and adaptor apoptotic protease 
activating factor-1 (Apaf-1) in the cytoplasm [Bai 2006]. This complex activates caspase-
9, in turn, the activated caspase-9 forms a large multi-protein structure known as the 
apoptosome in combination with the cytochrome c, ATP and Apaf-1. As a result, caspase-
3, 6, and 7 are activated and initiate the degradation, leading to apoptosis [Bai 2006, 
Khan 2007].  
 
 In contrast, the extrinsic pathway is initiated outside the cell through the 
transmembrane death receptors such as the Fas receptors on the cell membrane 
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[Ashkenazi 1998, Khan 2007]. The signal molecules released from other cells bind to 
transmembrane death receptors on the target cell to induce apoptosis. The extrinsic 
pathway initiates a signaling cascade and induces the activation of the caspase system 
independently of the p53 protein. However, both the pathways induce caspase-3 
activation. 
 
 
1.5.2 Anti-Angiogenesis 
 
 Angiogenesis represents a process of a new vessel formation from pre-existing 
endothelial vessels. The angiogenesis is an important process for wound healing as well 
as tumor growth and metastasis [Oak 2005, Rundhaug 2003]. It is different from the 
vasculogenesis, forming new blood vessels in the absence of existing blood vessels. 
Angiogenesis involves proteolysis of the extracellular matrix, proliferation and migration 
of endothelial cells, as well as synthesis of new matrix components [Rundhaug 2003, 
Stoclet 2004]. The matrix metalloproteinases (MMPs) play an important role in 
degradation of the surrounding extracellular matrix and basement membrane. They allow 
endothelial cells to detach and migrate into a new tissue during angiogenesis. They are 
also able to release pro-angiogenic factors such as bFGF, VEGF, and TGFβ [Oak 2005, 
Rundhaug 2003].  
 
 Recent studies have showed ellagic acid chelates divalent cations such as Zn2+ 
and Cu2+, inactivating MMPs, thus inducing anti-angiogenesis [Labrecque 2005, Loo 
2003, Oak 2005, Stoclet 2004]. Chelation of copper ions affects the function of 
angiogenic growth factors, thus inhibiting the angiogenic process in tumor cells 
[Aggarwal 2006, Oak 2005]. As a result of the action of ellagic acid, tumor growth and 
formation of new blood vessels can be suppressed by lowering level of the copper supply. 
In this regard, controlling the actions of the cellular and molecular levels via anti-
angiogenic mechanism will provide a novel approach for cancer treatment. 
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CHAPTER 2. OBJECTIVES AND HYPOTHESES 
 
 
2.1 Overall Goals 
 
 The overall objective of this project was to develop an implantable polymeric 
system as a novel drug delivery approach for a local chemotherapy. A variety of 
implantable polymeric devices have been applied for controlled drug release. In this 
project, chitosan, a cationic natural polymer, was employed as a drug carrier for sustained 
drug release, biocompatibility and biodegradation. Ellagic acid (EA), a naturally 
occurring phenolic compound, was incorporated into the chitosan polymer network to 
provide anti-cancer activity at a local targeted site.  
  
 The rationale for this project relates to sustained delivery of ellagic acid for a 
cancer treatment. Ellagic acid has been supplied as a dietary source to reduce the risk of 
cancer. However, such dietary phenolic compounds have the limited bioavailability 
because of their poor absorption and high metabolism in human body. In an attempt to 
maximize therapeutic efficacy and safety, the studies performed herein present 
implantable chitosan based drug carriers for local delivery of ellagic acid and their 
biological activities. The combination of the chitosan with the ellagic acid suggests a 
novel drug delivery to avoid a rapid loss of efficacy and significant toxicity into body. 
Chitosan/ellagic acid delivery systems were fabricated and investigated regarding 
localized effect of ellagic acid against cancer cells in vitro and in vivo. 
 
 Chapter 3 in this project gives a description of development and characterization 
of chitosan/ellagic acid composite films and presents their anti-cancer activities against a 
human melanoma skin cancer. This section discusses the feasibility of the use of ellagic 
acid in a chitosan film and localized effect of ellagic acid for a cancer treatment. Chapter 
4 discusses the potential mechanisms by which the chitosan/ellagic acid composite 
materials induce anti-proliferative effect against malignant glioma cells. This section also 
presents an animal model for brain glioma study focusing efficacy and safety of local 
treatment in vivo. Chapter 5 gives a description of a chitosan based thermo-sensitive gel 
for a local delivery of ellagic acid using a simple injection. This section emphasizes the 
mechanism of the sol-gel transition and discusses the biocompatibility of the delivery 
system as well as the anti-tumor activity of ellagic acid. While the first two sections 
present a surgically implantable delivery system with therapeutic efficacy, the third 
section focuses on developing injectable thermo-sensitive gel. The motivation for the 
selection of the injectable delivery relates to clinical application for a non-surgical 
implantation to avoid additional costs and surgical pains. Chapter 6 summarizes and 
discusses findings of this project. Finally, chapter 7 suggests future works for this study. 
 
 
2.2 Specific Hypotheses 
 
 Overall hypothesis is that chitosan/ellagic acid composite materials induce anti-
cancer activity in local targeted sites by inducing apoptotic death and suppressing 
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angiogenesis. In order to test the overall hypothesis, eight specific hypotheses are 
formulated as follows: 
 
 
2.2.1 Development of the Chitosan/Ellagic Acid Composite Films 
 
Hypothesis 1: Ellagic acid is chemically conjugated and embedded into chitosan 
polymer for a local delivery.  
Hypothesis 2: Chitosan/ellagic acid composite films biodegrade and provide a 
sustained slow release of ellagic acid at targeted areas. 
 
 
2.2.2 In vitro Anti-Cancer Activity of Chitosan/Ellagic Acid Composite Films  
 
Hypothesis 3: Anti-cancer activity of chitosan/ellagic acid composite films is 
attributed to ellagic acid in a dose-dependent manner.  
Hypothesis 4: Chitosan/ellagic acid composite films localize therapeutic effect via 
slow release of ellagic acid. 
Hypothesis 5: Apoptosis and anti-angiogenesis are the mechanisms by which the 
composite films inhibit the growth of cancer cells. 
 
 
2.2.3 In vivo Anti-Cancer Activity of a Chitosan/Ellagic Acid Composite Film in a 
Glioma Brain Cancer Model 
 
Hypothesis 6: A chitosan/ellagic acid composite film inhibits tumor growth in vivo 
using a subcutaneous model.  
 
 
2.2.4 An Injectable Gel System for a Local Delivery of Ellagic Acid 
 
Hypothesis 7: A liquid chitosan formulation forms a heat-induced chitosan gel at body 
temperature. 
Hypothesis 8: A thermo-sensitive chitosan gel is biocompatible and delivers anti-
cancer activity of ellagic acid via a simple injection.  
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CHAPTER 3. DEVEOPMENT OF CHITOSAN/ELLAGIC ACID FILMS AS A 
LOCAL DRUG DELIVERY SYSTEM TO INDUCE APOPTOTIC DEATH OF 
HUMAN MELANOMA CELLS ∗
 In recent years, the implantable polymeric system has gained special attention in 
order to treat localized diseases or cancers in specific anatomical sites such as the skin 
[Castro 2003, Chen 2003], bone [Withrow 2004], brain [Dhanikula 2004, Ewend 1996, 
 
 
 
3.1 Summary 
 
 This study was designed to develop a local delivery of ellagic acid (EA) using a 
natural chitosan polymer for cancer treatment. Chitosan/ellagic acid (Ch/EA) composite 
films were fabricated according to various concentrations of 0, 0.05, 0.1, 0.5, and 1% 
(w/v) of ellagic acid and characterized using Fourier transform infrared spectroscopy 
(FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and contact 
angle measurement. The WM115 human melanoma cell line was used as a skin cancer 
model while HS68 human newborn fibroblast cell line was tested as a control. Anti-
cancer activities of the composite films were evaluated by measuring the number of 
viable cells using MTS assay and apoptosis assay. With increasing concentration of 
ellagic acid, the composite films exhibited increasing amide and ester linkages and 
diffraction peaks of the crystallized ellagic acid. In addition, the increasing ellagic acid in 
composite films enhanced surface roughness and hydrophilicity. Viability of melanoma 
cells cultured on the composite films containing 0.5% (w/v) of ellagic acid or higher was 
lower than that on chitosan film by at least 11 times for 3 days incubation. This result 
clearly demonstrated that Ch/EA composite films have the localized anti-cancer activity 
in an ellagic acid concentration-dependent manner by inducing apoptotic cell death.  
 
 
3.2 Introduction 
 
 It is well known that the consumption of fruits and vegetables containing 
phytochemical rich compounds is helpful to reduce the risk of cancer [Mertens-Talcott 
2003, Stoclet 2004]. Such dietary substances include a variety of chemical compounds 
such as phenolic acids possessing a single ring structure and flavonoids holding several 
hydroxyl groups associated with phenolic groups [Scalbert 2000]. Ellagic acid is one of 
naturally occurring phenolic compounds and presents in fruits and nuts such as 
blueberries, red raspberries, pomegranates, walnuts, and grape seeds [Mullen 2003]. 
Ellagic acid has been reported to have anti-cancer properties via cell cycle arrest, 
induction of apoptosis, and inhibition of tumor formation and growth [Labrecque 2005, 
Losso 2004, Narayanan 1999, Whitley 2003].  
 
                                            
∗ Adapted with permission of Wiley Periodicals. Kim S, Liu Y, Gaber MW, Bumgardner 
JD, Haggard WO, Yang Y. Development of chitosan-ellagic acid films as a local drug 
delivery system to induce apoptotic death of human melanoma cells. J Biomed Mater Res 
Part B: Appl Biomater. 2009;90B:145-155. 
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Hammoud 2003], cervix [Keskar 2006], lung [Harper 1999], liver [Vog l 2002], and 
bladder [Lu 2004]. Compared with conventional chemotherapy, these delivery systems 
are designed to maintain the sufficient drug dose at a local target site over the necessary 
duration. This local drug delivery has a potential to reduce the toxic effect of the drug to 
the surrounding tissues as well. Polymeric delivery systems include synthetic (e.g., poly 
(D, L-lactideco- glycolide), poly (ethylene-co-vinyl acetate), polyphosphoester, and 
HPMA) or natural (e.g., chitosan, collagen, and gelatin) polymers. They have been used 
in a variety of forms such as films, sponges, beads, gels, patches, and ointments.  
 
 Particularly, chitosan, a cationic natural polymer produced by alkaline N-
deacetylation of chitin, provides useful characteristics such as biocompatibility, 
biodegradability, film forming property with mechanical strength, low toxicity, and low 
cost [Jaworska 2003, Tien 2003]. It has been extensively used over a wide range of 
applications including drug carriers, wound-healing agents, and tissue regeneration 
[Prashanth 2005, Ravi Kumar 2006, Yuan Y 2007]. The important characteristics of 
chitosan are dependent on its molecular weight, degree of deacetylation, crytallinity, 
viscosity, pKa, and etc [Pillai 2009]. In acidic environments, positively charged free 
amino groups of chitosan can form complexes with negatively charged molecules altering 
its physicochemical characteristics [Chatelet 2001, Wang 2006]. A number of amino 
groups that are available for chemical reaction with anionic drug or polymeric systems 
provide promising biomedical applications. In addition, the uniqueness of chitosan 
among polysaccharides is its susceptibility to enzymatic depolymerization and supply of 
cell activating oligomers and N-acetylglucosamine for rebuilding of other biological 
events [Stokke 1995]. 
 
 Melanoma, the most deadly skin cancer, is a malignant tumor of melanocytes and 
the retinal pigment epithelial cells [Smith 2002]. Sun exposure has long been known as a 
main cause in the development of skin cancer because of its UVA (320-400nm) and UVB 
(280-320nm) components causing DNA mutations [Hersey 2006, Brenner 2005]. 
Although the malignant melanoma in the early stage can be cured by surgery, there still 
remains a high risk of recurrence and rapid metastasis to other organs. Therefore, 
chemotherapy is mostly applied after surgery, but sometimes low therapeutic efficacy 
impacts the quality of the patient’s [Demierre 2006, Hussein 2003]. In this regard, the 
targeting of the molecules such as p53 [Gartel 2002, Hussein 2003], Bcl-2 family proteins 
[Chen 2002, Rieber 2001], TRAIL-related molecules [Hersey 2006], and certain elements 
of the Fas pathway [Kim 2006] to induce the apoptosis will provide a new approach to 
treat the recurrent tumor. The induction of apoptosis in the melanoma generally involves 
the activation of a complex array of caspases through two principal pathways, which are 
the transmembrane extrinsic pathway and the mitochondrial intrinsic pathway. These two 
pathways can be amplified through mitochondrial damage [Hersey 2006]. The 
mechanism responsible for apoptosis in malignant melanoma is still unclear. However, 
apoptotic cell death via these therapeutic approaches would be expected to minimize 
inflammatory effects causing the damage in the surrounding tissue [Willingham 1999].  
 
 In the present study, the chitosan/ellagic acid (Ch/EA) composite films were 
developed and characterized in terms of chemical structure, crystallinity, and surface 
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morphology. The biological effect of the composite films was evaluated using WM115 
human melanoma and HS68 human newborn fibroblast. It was hypothesized that the 
Ch/EA composite films impart an anti-proliferative effect against the melanoma cells by 
inducing apoptosis in an ellagic acid-concentration dependent manner. 
 
 
3.3 Materials and Methods 
 
 
3.3.1 Materials 
 
 The chitosan was purchased from Sigma Aldrich in medium molecular weight 
(190-310 kDa) with ~ 85% of a degree of deacetylation. The ellagic acid was also 
obtained from Sigma Aldrich. Fetal bovine serum (FBS), trypsin-EDTA, L-glutamine, 
antibiotic–antimycotic, phosphate buffered saline (PBS), and Dulbecco’s Modified Eagle 
Medium (DMEM) were obtained from GibcoTM. The Annexin V-PE and 7-AAD (7-
amino-actinomycin D) staining solution were purchased from BD Biosciences. The 
WM115 human melanoma and HS68 human newborn fibroblast cell lines were 
purchased from and cultured as per American Type Culture Collection (ATCC) 
instructions.  
 
 
3.3.2 Preparation of Chitosan Films (Ch) 
 
 A 1% (w/v) chitosan solution was prepared by stirring powdered chitosan in 
0.75% (v/v) aqueous acetic acid at room temperature overnight. The insoluble particles in 
the chitosan solution were removed by filtration. The chitosan solution was dialyzed at 
room temperature using a dialysis membrane, which was placed in a container filled with 
the distilled water for 6 days to reduce the acidity attributed to acetic acid. The final pH 
value of the chitosan solution was around 6.6. The neutralized chitosan solution was 
autoclaved at 121°C for 20 min and cast in nonstick plates and dried by evaporation for 1 
day. The dry transparent film was carefully peeled off from the plates, washed with 
distilled water to remove salt, and then air-dried in the biological hood. 
 
 
3.3.3 Preparation of Chitosan/Ellagic Acid (Ch/EA) Composite Films  
 
 The ellagic acid solutions in the distilled water (0.05, 0.1, 0.5, and 1% (w/v)) 
were prepared. The powdered ellagic acid was dissolved into the distilled water by adding 
several drops of 0.1M NaOH, with constant stirring at room temperature overnight. The 
1% (w/v) chitosan solutions were then mixed with the ellagic acid solutions at a chitosan 
to ellagic acid volume ratio of 1:1. The mixed Ch/EA solutions were agitated at 40°C for 
2 hours and were then neutralized for 3 or 4 days using dialysis membranes to reach the 
final pH values, ranging from 6.1 to 6.6. The Ch/EA solutions were autoclaved at 121°C 
for 20 min and cast in nonstick plates and dried by evaporation for 1 day in the biological 
hood. The chitosan/ellagic acid composite films (Ch/EA0.05, Ch/EA0.1, Ch/EA0.5, and 
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Ch/EA1) were carefully peeled off from the plates, washed with distilled water to remove 
salt, and then air-dried in the biological hood. 
 
 
3.3.4 FTIR Spectra 
 
 To characterize the surface functional groups of chitosan and Ch/EA composite 
films (Ch/EA0.05, Ch/EA0.1, Ch/EA0.5, and Ch/EA1), FTIR spectra were obtained 
using the BRUKER (TENSOR 27) spectrophotometer coupled to a PC with the analysis 
software. FTIR was used to investigate the surface chemical information according to 
different concentration of ellagic acid. The films were placed in the holder directly in the 
IR laser beam. All spectra were recorded by the transmittance mode (100 times scanning, 
4000-800 cm-1). 
 
 
3.3.5 X-Ray Diffraction 
 
 XRD was used to characterize the crystal structure of the films, which is related 
to mechanical strength and biodegradation rate. The XRD patterns were determined using 
an Advance D8 X-ray diffractometer (Bruker AXS, Madison, WI) and Kα Cu radiation 
with the voltage of 40 kV and the intensity of 40 mA. The crystal structure of ellagic acid 
in powder and Ch/EA composite films was examined by measuring the X-ray powder 
diffraction patterns. The data were collected over 2θ angular range from 4° to 40° in 
continuous mode with a scan rate of 0.75°/min and then X-ray diffractograms were 
displayed. 
 
 
3.3.6 Scanning Electron Microscopy 
 
 The morphology of the films was observed by scanning electron microscope 
(JEOL, JSM-6460LV). SEM was used to investigate the different surface morphology of 
composite films according to different concentration of ellagic acid. The films were 
coated with a gold layer and examined at a 10 kV accelerating voltage with a working 
distance of 11 mm. 
 
 
3.3.7 Water Contact Angle Determination 
 
 Water contact angle was used to determine wettability of Ch/EA composite films. 
The water contact angle of the films was measured using the VCA OPTIMA from the 
AST Products (Boston, MA). The samples (five samples per group) were coated onto 
glass slides and placed on the sample stage. The sessile drop method was used to measure 
the contact angle of the samples immediately. Distilled water droplets were dropped at 
five different sites on each slide sample, and then the mean and standard deviation values 
were calculated. All measurements were performed at ambient temperature. 
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3.3.8 Cell Culture 
 
 The WM115 human melanoma cell line and HS68 human newborn fibroblast cell 
line were grown and maintained in DMEM media with 10% FBS, 1% 
antibiotic/antimycotic mixture, 5 mL of L-glutamine (200 mM), and sodium pyruvate. 
The cells were cultured in an incubator supplied with 5% CO2 at 37°C. The culture 
medium was changed every 3 days. 
 
3.3.8.1 Cell Viability-Direct Contact 
 
 To determine the biological effect of the Ch/EA composite films on the two cell 
lines, the numbers of viable cells (melanoma and fibroblasts) were measured by MTS 
assay, and the cell morphology was observed by microscope (Nikon ECLIPSE TE-2000-
U). 150 µl of the sterilized samples was coated onto each well of 48-well plates and dried 
at room temperature, followed by rinsing with PBS (pH 7.4) twice, and then dried again. 
The cells were seeded on each sample at a density of 30,000 cells per well and cultured 
without medium exchange for 4, 24, and 72 hours. At the end of the incubation period, 
the cell viability was determined with the Cell Titer 96AQueous One Solution Cell 
Proliferation Assay (MTS assay, Promega Corp.). Each 60 µL of Cell Titer 96AQueous 
One Solution was added into each well of the 48-well plate containing the samples in 300 
µL of culture medium. Following an incubation period of 2 hours at 37°C 5% CO2, 100 
µL of solution in each well of the 48-well plate was transferred into the 96-well assay 
plates and the light absorbance at 490 nm was recorded using a micro-plate reader 
(Molecular Device Vmax kinetic). The background absorbance at 490 nm was corrected 
by subtracting the average absorbance of the control wells without cells from each well to 
estimate viable cellular activity. Prior to the MTS assay, the cell morphology was 
documented using an inverted bright field (BF) microscope (Nikon ECLIPSE TE-2000U) 
and processed using MetaVue software. 
 
3.3.8.2 Cell Viability-Indirect Contact 
 
 The indirect culture via BD BioCoatTM Control Cell Culture inserts (12-well 
formats) was used to evaluate the effect of the Ch/EA composite films on cell viability 
via cell culture media. The insert contains a 0.45-µm pore size PET membrane with a thin 
layer of basement membrane matrix, which prevents cells from migrating through the 
membrane, and allows only the culture medium to permeate through the PET membrane. 
The bottom of each well plate was coated with 700 µL of the sterilized samples and dried 
at room temperature, followed by rinsing with PBS (pH 7.4) twice, and then dried again. 
Cell culture medium (1.7 mL) was added into each well of the 12-well plate with inserts, 
which were allowed to hydrate for 2 hours at 37°C. The melanoma cells were then seeded 
at a density of 60,000 cells per well on the upper chamber with 0.3 mL of the culture 
medium. After the incubation for 4, 24, and 72 hours, the number of viable cells was 
determined using the Cell Titer 96AQueous One Solution according to the manufacturer’s 
instructions. 
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3.3.8.3 Cell Viability-at the Interface of the Presence and Absence of the Material 
 
 The localized effect of the Ch/EA composite film on cells was evaluated by 
observing the cellular behavior at the interface of the presence and absence of the 
material. The chitosan solution containing 1% (w/v) of ellagic acid (Ch/EA1) was coated 
on the half area of each 12-well plate. The cells were then seeded into the 12-well plate. 
At 4, 24, and 72 hours incubation, the cell morphology at the boundary between the non-
treated culture plate and the Ch/EA1 was observed using a microscope (Nikon ECLIPSE 
TE-2000U). 
 
 
3.3.9 Apoptosis Assay 
 
 To verify the statement that the Ch/EA composite films inhibit the cancer cell 
growth via induction of apoptosis, Annexin V-PE and 7-AAD (7-amino-actinomycin D) 
staining was performed. The phospholipids phosphatidylserine (PS) on the membrane of 
the apoptotic cells is translocated from the inner to the outer leaflet of the plasma 
membrane resulting in exposing PS to the external cellular environment. The Annexin V 
detects the PS on the outer plasma membrane at the early stage of apoptosis, whereas the 
7-AAD evaluates the progressive loss of the membrane permeability and discriminates 
apoptosis at the end stage of the apoptotic or dead cells [Kuypers 1996]. The early 
apoptotic cells are the Annexin V-PE positive and the 7-AAD negative, whereas the late 
apoptotic or dead cells are both V-PE and 7-AAD positive [Chen 2002, Kim 2006]. The 
melanoma cells were seeded on the 6-well plates coated with Ch/EA0.5 at a density of 
500,000 cells per well. The cells were incubated for 2 and 24 hours. At the end of the 
designated incubation period, both the floating and adherent cells were collected by 
trypsin, rinsed with the ice-cold PBS, and transferred into a 15 mL capacity centrifuge 
tube. After centrifugation at 1,200 rpm for 10 min, the cells were rinsed with ice-cold 
PBS, centrifuged again, and then resuspended. Subsequently, 100 µL of the solution 
containing 100,000 cells was transferred into a 5 mL culture tube before 5 µL of the 
Annexin V-PE and 7-AAD were added by gentle vortexing. After incubating the 5 mL 
culture tube for 15 min at room temperature in the dark, 400 µL of the binding buffer was 
added prior to the analysis. The apoptotic cells were determined using the Flow 
Cytometer (Becton-Dickson FACS Caliber). The total percentage of the apoptotic cells 
was calculated and the results were expressed as mean ± SD.  
 
 
3.3.10 Statistical Analysis 
 
 All data are presented as mean ± standard deviation. Significant differences in 
cell viability and apoptosis were analyzed by one-way ANOVA test. The differences in 
groups and experimental time points were considered significant if p<0.05. 
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3.4 Results 
 
 
3.4.1 FTIR Spectra 
 
 The FTIR spectra obtained from the chitosan film and Ch/EA composite films 
are shown in Figure 3.1. The spectrum of the chitosan film (Ch) exhibited several 
characteristic peaks which were attributed to the C=O stretch of amide I bond at 1652 and 
1559 cm-1, the N-H bending vibrations of amide II at 1409 and 1381 cm-1, and the C-N 
bending of the amine groups at 1323 cm-1. The peaks at 1075 and 1036 cm-1, 
representative of the C-O-C bending, were observed. Compared with the chitosan film, 
the spectra of the Ch/EA composite films showed greater intensity of the peaks at 1563 
and 1352 cm-1, which were assigned to the C=O stretch of the amide I bond and the N-H 
bending vibrations of the amide II, respectively. Furthermore, a new peak attributed to the 
aromatic C=C stretching was observed at 1507 cm-1. With increasing concentration of 
ellagic acid (Ch/EA0.5), the intensity of amine groups of the chitosan film decreased at 
1330 cm-1. In addition, a strong ester linkage because of the C=O stretch appeared around 
1060 cm-1. 
 
 
3.4.2 X-Ray Diffraction 
 
 XRD patterns of the ellagic acid in the powder and the Ch/EA composite films 
were used to determine the differences in the crystal structures. Several strong diffraction 
peaks were observed in the powdered ellagic acid at the following 2θ of 9.6°, 10.5°, 12.3°, 
13.6°, 17.5°, 20.7°, 25.1°, 26.4°, 28.3°, 32.1°, 34.7°, 35.4°, 36.9°, 37.6°, and 39.1° 
(Figure 3.2a). The diffractogram of a neutralized chitosan film displayed two major 
crystalline peaks at 2θ of 10.5° and 21° with a characteristic broad hump as shown in 
Figure 3.2b(1). The Ch/EA0.05 and Ch/EA0.1 became amorphous and did not show any 
reflective peaks, but exhibited a broad halo at 2θ of around 23° as shown in Figure 
3.2b(2) and (3). With increasing concentration of ellagic acid as shown in Figure 3.2b(4) 
and (5), several diffraction peaks were observed in the Ch/EA0.5 at 2θ of 9.6°, 12.3°, 
13.6° and in the Ch/EA1 at 2θ of 9.6°, 12.3°, 13.6°, 17.5°, 28.3°. This result 
demonstrated that the newly appeared peaks were assigned to the crystal structure of 
ellagic acid. 
 
 
3.4.3 Scanning Electron Microscopy 
 
 Figure 3.3 displays the SEM micrographs of the Ch/EA composite films. The 
morphological difference was observed on the surface of each film. The surface 
morphology of Ch/EA0.05 (Figure 3.3a) was fairly smooth and almost similar to that of 
the chitosan film. However, the surface morphologies of the other films became rougher 
and more heterogeneous with increasing concentration of ellagic acid as shown in Figure 
3.3b-d.  
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Figure 3.1 FTIR spectra of the chitosan/ellagic acid composite films with  varying 
concentration of the ellagic acid. (a) Ch (neutralized chitosan film); (b) Ch/EA0.05; (c) 
Ch/EA0.1; (d) Ch/EA0.5.  
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Figure 3.2 X-ray diffraction patterns. (a) the ellagic acid in powder and (b) the 
chitosan/ellagic acid composite films with varying concentration of the ellagic acid. (1) 
Ch (neutralized chitosan film); (2) Ch/EA0.05; (3) Ch/EA0.1; (4) Ch/EA0.5; (5) Ch/EA1 
at ambient temperature. 
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Figure 3.3 SEM micrographs on the surface of the chitosan/ellagic acid composite films 
with varying concentration of the ellagic acid. (a) Ch/EA0.05; (b) Ch/EA0.1; (c) 
Ch/EA0.5; (d) Ch/EA1. (MAG = ×1000) 
 
 
 
 
 
 
 
 
  (a)   (b) 
  (c)   (d) 
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3.4.4 Water Contact Angle Determination 
 
 The effect of concentration of ellagic acid on the hydrophilicity of the Ch/EA 
composite films is shown in Table 3.1. The measurement of water contact angle was 
performed to study the wettability of the composite films containing various 
concentration of ellagic acid. The water contact angles on the composite films decreased 
with increasing concentration of the ellagic acid. This result indicated that the surface of 
the composite films became more hydrophilic with increasing concentration of ellagic 
acid and rougher surface shown in Figure 3.3c and d. 
 
 
3.4.5 Cell Viability-Direct Contact 
 
 We evaluated the effect of the Ch/EA composite films on the growth of the 
melanoma cells and fibroblasts by microscopy and MTS assay. The microscopic 
observation shows the morphological changes of the WM115 human melanoma cells 
(Figure 3.4) and HS68 human newborn fibroblasts (Figure 3.5) on Ch/EA composite 
films at 4 and 72 hours of incubation, respectively. The melanoma cells first adhered to 
all the films in round shape at 4 hours of the incubation as shown in Figure 3.4a–f. After 
72 hours of the incubation, the melanoma cells appeared to aggregate on the chitosan film, 
Ch/EA0.05, and Ch/EA0.1 as shown in Figure 3.4h-j. However, as shown in Figure 3.4k 
and l, the melanoma cells retained their round shaped on the Ch/EA0.5 and Ch/EA1 and 
the aggregation of the cells did not occur for 3 days of cell culture.  
 
 Similarly, the fibroblasts first adhered to all the films in a round shape at 4 hours 
of the incubation as shown in Figure 3.5a-f. After 72 hours of the incubation, the 
fibroblasts changed their morphologies from circular to spindle shaped on the chitosan 
film, Ch/EA0.05, and Ch/EA0.1 as shown in Figure 3.5h-j. This observation indicates the 
growth and proliferation of the cells. However, the fibroblasts still exhibited a round 
shape on the Ch/EA0.5 and Ch/EA1 as shown in Figure 3.5k and l.  
 
 In addition to a morphological change, there were significant increases in the cell 
viability of the melanoma (Figure 3.6a) on the chitosan film and Ch/EA0.05 after 24 and 
72 hours of the incubation compared with 4 hours (p<0.05). However, the cell viability 
was slightly decreased on the Ch/EA0.05 after 72 hours of the incubation compared with 
24 hours, but no significant change was observed (p=0.17).  
 
 
Table 3.1 Water contact angles of the chitosan/ellagic acid composite films. 
 
 Chitosan Ch/EA0.05 Ch/EA0.1 Ch/EA0.5 Ch/EA1 
Contact 
angle 103.62 ±3.9 99.87±3.16 97.39±2.35 94.75±4.4 88.02±2.61 
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Figure 3.4 Photomicrographs of WM115 melanoma cells cultured on the chitosan 
coatings containing various concentration of ellagic acid. (a) no treatment; (b) chitosan 
film; (c) Ch/EA0.05; (d) Ch/EA0.1; (e) Ch/EA0.5; (f) Ch/EA1 for 4 hours of the 
incubation. (g) no treatment (tissue culture plate); (h) chitosan film; (i) Ch/EA0.05; (j) 
Ch/EA0.1; (k) Ch/EA0.5; (l) Ch/EA1 for 72 hours of the incubation. The initial cell 
density was 30,000 cells per well. (MAG = ×100). Arrows indicate cells on the coating 
material. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 (continued).  
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Figure 3.5 Photomicrographs of HS68 fibroblasts cultured on the chitosan coatings 
containing various concentration of ellagic acid. (a) no treatment; (b) chitosan film; (c) 
Ch/EA0.05; (d) Ch/EA0.1; (e) Ch/EA0.5; (f) Ch/EA1 for 4 hours of the incubation. (g) 
no treatment (tissue culture plate); (h) chitosan film; (i) Ch/EA0.05; (j) Ch/EA0.1; (k) 
Ch/EA0.5; (l) Ch/EA1 for 72 hours of the incubation. The initial cell density was 30,000 
cells / well. (MAG = ×100) Arrows indicate cells on the coating material. 
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Figure 3.5 (continued).  
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Figure 3.6 Viability of (a) WM115 melanomas and (b) HS68 fibroblasts via direct contact 
culture by MTS assay. The cells were cultured directly on each sample at a density of 
30,000 cells per well without changing medium for 4, 24, and 72 hours. The absorbance 
expressed as a measure of cell viability on the chitosan coatings with varying 
concentration of ellagic acid for 3 days incubation: The initial cell density was 30,000 
cells per well, respectively. * denotes significantly different cell viability compared with 
chitosan film, Ch/EA0.05, and Ch/EA0.1 at 4, 24, and 72 hours incubation (p<0.05). 
Each value represents the mean ± SD (n = 6 per each group). 
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The significant decreases in the melanoma cell viability on the Ch/EA0.1 (Figure 
3.6a) were observed after 72 hours compared with 4 and 24 hours (p<0.05), suggesting 
the inhibitory effect of the Ch/EA0.1 on the melanoma cells. For fibroblasts cultured on 
the composite films (Figure 3.6b), there were significant increases in cell viability on the 
chitosan film and Ch/EA0.05 after 72 hours of the incubation compared with 4 and 24 
hours (p<0.05). The cell viability on the Ch/EA0.1 after 72 hours incubation slightly 
increased compared with 4 hours, but no significant changes were observed (p=0.24).  
 
 As shown in Figure 3.6a and b, on the surface of the Ch/EA0.5 and Ch/EA1, the 
numbers of viable cells including fibroblasts and melanoma were found to decrease 
significantly over the 72 hours of the incubation (p<0.05). In addition, both the cells on 
the Ch/EA0.5 and Ch/EA1 exhibited significantly lower viability compared with the cells 
on the chitosan film, Ch/EA0.05, and Ch/EA0.1 at 4, 24, and 72 hours of the incubation. 
 
 
3.4.6 Cell Viability-Indirect Contact 
 
 The indirect contact culture was used to evaluate the effect of the released ellagic 
acid from the Ch/EA composite films into the cell culture medium on the viability of the 
melanoma cells for 4, 24, and 72 hours of incubation, respectively. Figure 3.7 shows that 
the melanoma cells in the absence of direct contact significantly proliferated regardless of 
the concentration of the ellagic acid after 72 hours of incubation compared with 4 hours 
(p<0.05). However, the melanoma cells in the absence of direct contact with the Ch/EA1 
exhibited significantly lower cell viability compared with the chitosan film at 72 hours of 
incubation (*p<0.05). This result reflected the inhibitory effect of high concentration of 
ellagic acid on cell proliferation in the absence of direct contact. There are no significant 
differences among other Ch/EA composite film groups. 
 
 
3.4.7 Cell Viability at the Interface of the Presence and Absence of the Material 
 
 In addition, Figure 3.8 shows the cellular morphology at the boundary between 
the non-treated culture plate control and the Ch/EA1. Both the melanoma cells (Figure 
3.8a) and fibroblasts (Figure 3.8b) on the non-treated culture plate close to the film areas 
were viable, well spread, and proliferated for 3 days, whereas the cells on the film areas 
did not change in morphology and the cell number decreased. These photomicrographs 
demonstrated that cell viability was significantly affected by direct contact of the 
composite films. This result suggests that the targeted area can be more effectively treated 
than the surrounding area. 
 
 
3.4.8 Apoptosis Assay 
 
 Generally, cell viability is determined by the mechanism of necrosis or apoptosis. 
Necrosis is the result of the destruction of the plasma membrane by external damage. On 
the other hand, apoptosis, which is much slower than necrosis, leads to highly controlled  
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Figure 3.7 Viability of WM115 melanomas via indirect contact culture by MTS assay. 
The cells seeded onto the permeable PET membrane were affected by the released ellagic 
acid into the culture medium. The absorbance expressed as a measure of WM115 cell 
viability from each sample for the time point indicated; initially, the cell density was 
60,000 cells per well. * denotes significantly different cell viability compared with the 
chitosan film at 72 hours incubation (p<0.05). Each value represents the mean ± SD (n = 
4 per each group). 
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Figure 3.8 Photomicrographs of (a) WM115 melanomas and (b) HS68 fibroblasts at the 
boundary between the absence and presence of Ch/EA1. The dark area indicates the cell 
morphology on the coating materials, and the bright area represents the cell morphology 
on the tissue culture plate (MAG = ×150). 
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cell death by biochemical and morphological events [Willingham 1999]. To determine 
whether the action of the Ch/EA composite films induce apoptotic cell death, the 
apoptosis assays using Annexin V-PE and 7-AAD were performed to quantify the 
percentages of the apoptotic cells. Because the higher decrease in the cell viability within 
a short time period occurred in the chitosan film containing 0.5 and 1% (w/v) of ellagic 
acid, in this study, the chitosan film containing 0.5% (w/v) of ellagic acid (Ch/EA0.5) 
was chosen to compare with the chitosan film as well as the untreated culture plate 
control.  
 
 As shown in Table 3.2, the cells experienced apoptosis even on the cell culture 
plate (control group). However, a significantly greater percentage (p<0.05) of the 
apoptotic cells on the Ch/EA0.5 was observed when compared with the culture plate 
control and the chitosan film. Besides, most of the apoptotic cells induced by the 
Ch/EA0.5 were populated in the early stage of apoptosis. This result was consistent with 
the result of the cell viability and proliferation at 24 hours of the incubation. Cell viability 
was significantly reduced by the treatment of the Ch/EA0.5 through apoptotic mechanism 
within 1 day.  
 
As shown in the surface morphological features (Figure 3.4), most of the 
melanoma cells cultured on the Ch/EA0.5 undergoing the apoptotic process remained a 
round shaped and shrunk in their morphologies with time. In contrast, the morphological 
changes of the melanoma cells cultured on the chitosan film were found. This result 
demonstrated that apoptotic cell death via these therapeutic approaches would be 
expected to minimize inflammatory effects causing the damage in the surrounding tissue 
and provide highly effective strategies for cancer treatment with minimal side effects. 
 
 
3.5 Discussion 
 
 In an attempt to apply a novel drug delivery system for cancer treatment, ellagic 
acid, a naturally occurring phenolic compound, was incorporated into the natural chitosan 
polymer. This study focused on development of chitosan/ellagic acid (Ch/EA) composite 
films and evaluation of their anti-cancer activities. The characteristics of the composite 
films were investigated regarding chemical structure, crystallinity, and surface 
morphology. The anti-cancer activities were compared according to different 
concentrations of ellagic acid and the localized effect was monitored via indirect cell 
culture and cellular morphological observation. The hypothesis was that the 
chitosan/ellagic acid composite films designed as a local drug delivery would present an 
anti-proliferative effect against the melanoma cells by inducing apoptosis.  
 
 Surface chemistry, crystallinity, and morphology of materials significantly 
influence the function of drug delivery system. The FTIR spectra revealed higher 
intensity peaks of amide and ester linkages in the Ch/EA composite films compared with 
the chitosan film. This is probably because the carboxylic groups (COOH) of the ellagic 
acid combined with the hydroxyl (OH) and amine (NH2) groups of the chitosan, resulting 
in increase in the amide and ester linkages [Tien 2003, Wang 2004]. 
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Table 3.2 Induction of apoptosis in melanoma cells cultured on the indicated samples for 
2 and 24 hours.  
 
 
Cells were harvested at a density of 5×105 cells/well and analyzed apoptosis using 
Annexin V-PE and 7-AAD. Results are expressed as the percentage of apoptotic cells that 
were either Annexin V-positive and 7AAD-negative (apoptotic cells in the early stage) or 
Annexin V-positive and 7AAD-positive (apoptotic cells in the end stage or necrotic cells). 
* denotes significant difference compared with control and chitosan groups at both 2 and 
24 hours incubation (p<<0.05). ** denotes significant difference compared with the early 
stage at both 2 and 24 hours incubation (p<<0.05). Each value represents the mean ± SD 
(n = 3 per each group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apoptosis  Control Chitosan Ch/EA0.5 
2 hours 
The early stage  10.17 ± 0.96 8.84 ± 0.99 34.15 ± 4.14 * 
The end stage  0.22 ± 0.06 6.25 ± 0.6 0.46 ± 0.03 ** 
24 hours 
The early stage 5.95 ± 1.26 9.43 ± 1.03 63.89 ± 3.24 * 
The end stage  6.32 ± 1.04 7.37 ± 0.94 3.16 ± 0.24 ** 
 43 
The surface of the composite films became rougher with increasing concentration 
of ellagic acid, thus indicating ellagic acid was physically entrapped into the chitosan 
polymer. The water contact angle of the Ch/EA composite films decreased with 
increasing concentration of ellagic acid, suggesting enhanced wettability of the composite 
films. The increased wettability is probably due to increase in functional groups of ellagic 
acid on the composite films [Amaral 2006, Neamnark 2007] and surface roughness as 
shown in SEM (Figure 3.3). As such, this study suggested that the concentration of 
ellagic acid influenced surface functional groups, surface roughness, and wettability of 
the Ch/EA composite film. Neutralized chitosan film showed a strong reflection of the 
hydrated crystal at 2θ of 10.5° and 21°, and a characteristic broad halo, which is an 
indicator of the amorphous form of the chitosan films [Jaworska 2003, Silvia 2004, 
Vishu-Kumar 2004]. These peaks disappeared in the XRD patterns of the Ch/EA0.05 and 
Ch/EA 0.1 and were replaced by a broad peak, suggesting a lower crystallinity or a less 
ordered structure than the chitosan film. On the other hand, new diffraction peaks were 
observed in the Ch/EA0.5 and Ch/EA1, which were assigned to the crystalline of ellagic 
acid.  
 Cell adhesion, growth, and proliferation on the material surface are the sequential 
responses, which are essential for cell survival and function [Findlay 2000, Willingham 
1999]. The morphological changes of the fibroblasts and melanoma cells cultured on the 
Ch/EA composite films reflected a direct cell response to the biological activity of the 
composite films. The HS68 human fibroblasts changed their morphology from a circular 
shape to spindle-like features over time on the surface of the chitosan film, Ch/EA 0.05, 
and Ch/EA 0.1. In addition, cell viability was also significantly increased with time, 
indicating no harmful effect of the chitosan film and Ch/EA 0.05 on fibroblasts. In 
contrast, the WM115 human melanoma cells cultured on the same films initially attached 
and then detached and aggregated, showing initial inhibitory effect of films on cell 
attachment. This result demonstrated that the chitosan film had initial inhibitory effect on 
cell growth and proliferation for short time periods but it could not prevent cell 
proliferation for long time periods. Several studies have suggested that the chitosan 
induces anti-bacterial and anti-tumor properties attributed to the tumor necrosis factor-α 
(TNF- α) in human monocytes [Muzzarelli 1997, Ravi Kumar 2006]. However, additional 
studies are needed to clarify the mechanism by which chitosan polymer influences the 
growth of cancer cells. However, with increasing concentration of ellagic acid (0.5 and 
1% (w/v)), both the fibroblasts and melanoma cells remained in the initial round shape 
and could not grow and proliferate. The number of viable cells was significantly reduced 
by treatment of the Ch/EA0.5 and Ch/EA1 even after 4 hours incubation. In other words, 
the cells initially adhered to the composite films, but they lost their viability within a few 
hours in an ellagic acid concentration dependent manner.  
 
 In addition, this study showed the biological activity of the Ch/EA composite 
films is localized. It was clearly supported by the cell behavior at the interface of the 
Ch/EA1 for 3 days incubation as shown in Figure 3.8. At the interface, both melanoma 
and fibroblasts could grow and proliferate well in the absence of direct contact on the 
Ch/EA1. However, cells lost their viability in the presence of direct contact on the 
Ch/EA1, and they remained a round shaped and shrunk in their morphologies with time. 
This result demonstrated that the Ch/EA composite films influence cell survival and 
 44 
growth mostly via direct contact, corresponding with slow release of ellagic acid from 
chitosan matrix into cell culture media. Additionally, the indirect contact culture showed 
the Ch/EA1 significantly slowed down the proliferation of melanoma cells compared 
with chitosan film. This result suggested that the chitosan film containing higher 
concentration of ellagic acid was able to regulate the cell growth via the released ellagic 
acid from chitosan film into culture medium. This study verified the localized and dose-
dependent effect of composite films on melanoma, which potentially made it possible to 
apply the composite films to treat cancers at targeted area.  
 
 The Ch/EA composite film could induce apoptotic cell death in a dose-dependent 
manner. Induction of apoptosis has been considered as a target of anti-cancer therapy. 
Apoptosis is a process of an essential tissue homeostasis, thus being regarded as an ideal 
way to treat cancer without significant influence on normal tissue [Bai 2006, Khan 2007]. 
Many studies have demonstrated that induction of apoptosis by anti-cancer drugs 
appeared in a dose- and time-dependent manner. [Khan 2007, Losso 2004, Narayanan 
1999] This study has an agreement with the fact that the Ch/EA composite films induce 
apoptotic cell death in an ellagic acid concentration dependent manner. In the present 
study, it has been discussed that a localized activity of the Ch/EA composite films is 
attributed to the unique characteristics of chitosan and ellagic acid. This novel approach 
showed a new clinical approach to treat cancer at a targeted site by induction of apoptosis, 
thus having certain advantages over conventional cancer chemotherapy.  
 
 
3.6 Conclusion 
 
 This study was to investigate the feasibility of a local delivery of ellagic acid 
using chitosan polymer for cancer treatment. In summary, ellagic acid was incorporated 
into the chitosan polymer chemically and physically. The concentration of ellagic acid 
influenced chemical structure, surface morphology, hydrophilicity, and crystallinity of the 
composite film. Additionally, the composite films were found to have a potent anti-cancer 
activity against melanoma cells in an ellagic acid concentration dependent manner and 
induce apoptotic cell death. It was concluded from this study that the Ch/EA composite 
film represents a new form of ellagic acid for a local cancer treatment.  
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CHAPTER 4. THE INHIBITION OF GLIOMA GROWTH IN VITRO AND IN 
VIVO BY A CHITOSAN/ELLAGIC ACID COMPOSITE BIOMATERIAL∗
                                            
∗ Adapted with permission of Elsevier. Kim S, Gaber MW, Zawaski JA, Zhang F, 
Richardson M, Zhang XA, Yang Y. The inhibition of glioma growth in vitro and in vivo 
by a chitosan/ellagic acid composite biomaterial. Biomaterials 2009;30:4743-4751.  
 
 
 
4.1 Summary 
 
 This study investigated the anti-cancer effect of a local delivery of ellagic acid 
against brain cancer. The Ch/EA composite films were fabricated according to different 
concentrations of ellagic acid. In vitro release study was performed by a UV 
spectrophotometer, and enzymatic degradation rate was determined by analyzing the 
increase in free amino groups. Viability of cancer cells (human U87 glioblastomas and rat 
C6 glioma cells) was measured via direct and indirect cell culture on the films by a MTS 
assay. To analyze anti-cancer mechanisms, caspase-3 activation, western blot for p53, and 
anti-angiogenesis assays were examined. In the in vivo study, GFP-tagged rat C6 glioma 
cells were implanted subcutaneously at the right flank region of nude mice, and 
treatments were initiated by implanting the films subcutaneously. Tumor growth was 
evaluated by measuring tumor volume using a caliper, an ultrasound machine, and an 
optical imaging system. The Ch/EA composite films were enzymatically degradable, 
indicated by at least a 5 times higher concentration of free amino groups in the incubation 
medium at 3 weeks compared with 1 day. They also exhibited a sustained slow release of 
ellagic acid without an initial burst effect. Tumor tissue growth in Ch/EA20 group was 9 
times lower than that in control groups at 3 weeks observation by measuring a caliper. It 
was concluded that the Ch/EA composite film can inhibit the growth of brain cancer cells 
in an ellagic acid concentration-dependent manner by inducing apoptosis of cancer cells 
as well as suppressing angiogenesis.  
 
 
4.2 Introduction 
 
 Primary brain tumors mostly arise from glial cells of the brain itself while 
secondary brain tumors are originated from the body and spread to the brain [Brandes 
2008, Cokgor 1998]. Abnormal growth of glial cells is responsible for the development of 
gliomas. The glioma includes any type of brain tumor such as astrocytoma, 
oligodendroglioma, and glioblastoma with a different function [Brandes 2008]. Glioma is 
classified into four grades according to its appearance under the microscope. Low-grade 
gliomas (grade I and II) are slow-growing and curable while high-grade gliomas (grade 
III and IV) are fast-growing, invasive, and frequently recur [Graham 2004]. Glioblastoma 
multiforme (GBM) is the most malignant brain tumor, infiltrating adjacent normal brain 
tissue. GBM spreads rapidly, invades other parts of the brain, and mostly recur after 
initial treatment [Brandes 2008]. It is a grade IV tumor which includes increase in cell 
population, abnormal cells and nuclei, necrosis and growth of blood vessels [Purow 
2004].  
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 It was reported that the median survival time of patients with malignant gliomas 
ranges from 14 weeks (no treatment) to 40-50 weeks despite aggressive multimodality 
management with surgery, radiation, and chemotherapy [Avgeropoulos 1999, Graham 
2004]. This is because high grade gliomas mostly recur locally. In this regard, local 
therapies combined with surgical intervention are regard as an ideal approach to improve 
the efficacy of treatments. Recent studies have focused on designing polymeric devices 
that allow local delivery of chemotherapeutics into the surgical resection cavity. In 
particular, for patients with brain cancer, these local delivery systems are safer and more 
beneficial compared with traditional chemotherapy [Avgeropoulos 1999, Moses 2003, 
Wang 2002]. These methods administer drugs directly into the brain, bypass the blood 
brain barrier (BBB), and deliver the drugs in a concentration dependent manner 
[Groothuis 2000, Purow 2004, Wang 2002]. Some clinical studies have demonstrated that 
local chemotherapy delivered by polymer carrier significantly prolongs the survival time 
of patients [Brem 1999, Cho 2008, Jain 2001, Walter 1994, Westphal 2003].  
 
 It is generally agreed that ellagic acid inhibits growth of cancer cells via 
induction of apoptosis or by suppressing angiogenesis. Ellagic acid induces G1 arrest and 
apoptosis by p53-mediated activation [Khan 2007, Mertens-Talcott 2005]. Unlike 
necrosis, apoptosis can reduce inflammatory response caused by cell death. Because the 
apoptotic function of p53 is critical for tumor suppression, induction of apoptosis through 
p53 activation may be an attractive strategy for anti-cancer treatment. Ellagic acid also 
inhibits angiogenesis via inactivating metalloproteinases by chelating divalent cations 
such as Zn2+ and Cu2+ [Khan 2007, Labrecque 2005, Laura 2001, Oak 2005]. As a result, 
tumor growth and formation of new blood vessels are possibly suppressed by lowering 
the level of such cations. The angiogenesis is an important process for tumor growth and 
metastasis. Therefore, controlling the actions of the cellular and molecular levels 
involved in angiogenesis provide novel therapeutic approaches for cancer treatment. 
Ellagic acid is currently used as a dietary supplement to reduce or prevent the risk of 
cancer. [Pinto 2008, Vekiari 2008] 
 
 However, most dietary phenolic products are poorly absorbed into the body, 
rapidly metabolized, and eliminated by digestive and hepatic activities or the bioactivities 
of phenolic metabolites in blood [Han 2007, Scalbert 2000]. This result leads to the 
absence of ellagic acid in blood or presence in very low concentrations [Shukla 2008]. In 
order to increase the bioavailability and maximize the anti-tumor activity, a local delivery 
system using a chitosan polymer has been developed and attempted to carry ellagic acid 
over a long period of time to treat brain cancers. Chitosan, a cationic natural biopolymer, 
can be readily formed into film-type or gel-type and is promising in the development of 
controlled-release systems [Kim 2009, Ravi Kumar 2004, Tien 2003]. It has been 
extensively used as a drug carrier, a wound healing agent, and for tissue regeneration in a 
variety of applications. The objective of this study was to further study release profiles, 
degradation behaviors, and to evaluate its biological effect and mechanism against brain 
cancers (human U87 glioblastomas and rat C6 glioma cells) in vitro and in vivo. It was 
hypothesized that Ch/EA composite films inhibit growth of glioma cancer by inducing 
apoptosis and suppressing angiogenesis. 
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4.3 Materials and Methods 
 
 
4.3.1 Materials 
 
 The chitosan with approximately 85% of a degree of deacetylation and ellagic 
acid were purchased from Sigma Aldrich. Fetal bovine serum (FBS), trypsin/EDTA, L-
glutamine, antibiotic/antimycotic, phosphate buffered saline (PBS), and Dulbecco’s 
Modified Eagle Medium (DMEM) were obtained from GibcoTM. Lysozyme (egg-white), 
glycine (crystalline/certified), and ninhydrin solution reagents were purchased from 
Fisher Scientific. The U87 human glioblastoma and C6 rat glioma cell lines were cultured 
as per American Type Culture Collection (ATCC) instructions. The Human Umbilical 
Vein Endothelial Cells (HUVEC) was purchased from and cultured as per Cascade 
BiologicsTM (Portland, OR, USA). 
 
 
4.3.2 Preparation of Chitosan Films (Ch) 
 
 A 1% (w/v) chitosan solution was prepared by stirring powdered chitosan in 
0.75% (v/v) aqueous acetic acid at room temperature overnight. It was followed by 
dialysis for 6 days using a dialysis membrane, and its final pH value was approximately 
6.6. The neutralized chitosan solution was autoclaved (120°C, 20 min), and a chitosan 
film was prepared by evaporation for 1 day. The dry transparent film was washed with 
distilled water to remove salt and then air dried in a biological hood. 
 
 
4.3.3 Preparation of Chitosan/Ellagic Acid (Ch/EA) Composite Films 
 
 Ellagic acid solutions were prepared according to different concentrations (0.05, 
0.1, 0.5,1, or 20% (w/v)) of ellagic acid powder. The ellagic acid was dissolved into 
distilled water by adding several drops of 0.1 M NaOH, with constant stirring at room 
temperature overnight. The chitosan solutions were then mixed with various ellagic acid 
solutions at a chitosan to ellagic acid volume ratio of 1:1. The mixed Ch/EA solutions 
were agitated at 40°C for 2 hours and were then neutralized for 3 or 4 days using dialysis 
membranes to reach the final pH values, ranging from 6.1 to 6.6. The Ch/EA solutions 
were autoclaved (120°C, 20 min) and cast in non-stick plates and dried by evaporation for 
1 day in the biological hood. Chitosan/ellagic acid composite films (Ch/EA0.05, 
Ch/EA0.1, Ch/EA0.5, Ch/EA1, and Ch/EA20) were carefully peeled off from the plates, 
washed with distilled water to remove salt, and then air-dried in a biological hood. 
 
 
4.3.4 In vitro Release Studies 
 
 Ellagic acid release from the Ch/EA composite films was quantified over time by 
an in vitro release assay. Chitosan/ellagic acid composite films (Ch/EA0.05, Ch/EA0.1, 
Ch/EA0.5, Ch/EA1, or Ch/EA20) were prepared from the same volume of each polymer 
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solution, which contains the same weight percentage of chitosan but different weight 
percentages of ellagic acid. The films were then cut and placed in containers containing 6 
mL of distilled water at 37°C. At designated time points (1, 3, 7, 14, and 21 days), 500 µL 
aliquots of the release medium were sampled and the same amount of fresh distilled 
water was added into the containers. In the collected fractions, the cumulative amount of 
ellagic acid released from the composite films was determined as a function of time by a 
UV spectrophotometer (ULTRASPEC 2100 PRO UV/Visible) at 260 nm. In addition, 
ellagic acid release in the presence of lysozyme (1 mg/mL) was also determined in order 
to examine the effect of an enzyme on the release profile. 
 
 
4.3.5 In vitro Enzymatic Degradation 
 
 The chitosan/ellagic acid composite films (chitosan, Ch/EA0.05, Ch/EA0.1, 
Ch/EA0.5, Ch/EA1, or Ch/EA20) were prepared after sterilization by autoclaving (120°C, 
20 min) and then digested in 24-well plates containing phosphate buffer saline (PBS, pH 
6) with 1 mg/mL lysozyme (egg-white, Fisher Scientific, Fair Lawn, NJ) at 37°C. In this 
study, the ninhydrin assay was performed to determine free amino groups in the 
incubation medium collected after the designated time points.  
 
 Two separate studies were performed to determine the degradation rates of 
Ch/EA composite films and the effect of the ratio of chitosan to ellagic acid on enzymatic 
degradation. The first study was to evaluate the effect of lysozyme on degradation of each 
sample with the same total weight (approximately 12 mg). The second study was to 
investigate the degradation rate of each sample with the same weight of chitosan but 
different weight percentages of ellagic acid. After the predetermined time points (1, 3, 7, 
14, and 21 days), 0.5 mL of the medium from each sample was collected and heated with 
0.5 mL of ninhydrin solution at 95°C for 10 min. After heating with ninhydrin solution, 
the light absorbance at 550 nm was recorded using a micro-plate reader (Molecular 
Device Vmax kinetic). The glycine (Fisher Scientific, Fair Lawn, NJ) was used as an 
amino acid nitrogen standard at various known concentrations. Because the amount of 
free amino groups is proportional to the optical absorbance of the solution, the enzymatic 
degradation rate can be determined by analyzing the increased N-glucosamine units in the 
incubation medium. 
 
 
4.3.6 Cell Culture 
 
 The U87 human glioblastomas were grown and maintained in DMEM media 
with 10% FBS, 1% antibiotic/antimycotic mixture, 5 mL of L-glutamine (200 mM), and 
sodium pyruvate. The C6 rat gliomas were grown and maintained in F-12K Media with 
2.5% FBS, 15% horse serum, 1% antibiotic/antimycotic mixture, 5 mL of L-glutamine 
(200 mM), and sodium pyruvate. The Human Umbilical Vein Endothelial Cells 
(HUVEC) were grown and maintained in Medium 200 with Low Serum Growth 
Supplement (LSGS) containing fetal bovine serum (2% v/v), hydrocortisone (1 mg/mL), 
human epidermal growth factor (10 ng/mL), basic fibroblast growth factor (3 ng/mL), 
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and heparin (10 mg/mL). The cells were cultured in an incubator supplied with 5% CO2 
at 37°C. The culture medium was changed every 3 days. 
 
4.3.6.1  In vitro Anti-Tumor Activity - Direct Cell Culture 
  
 To determine the biological effect of Ch/EA composite films on the two brain 
cancer cell lines, the numbers of viable cells (U87 and C6) were measured by a MTS 
assay. 150 µL of the sterilized samples was coated onto each well of 48-well plates and 
dried at room temperature followed by rinsing with PBS (pH 7.4) twice and then dried 
again. The cells were seeded on each sample at a density of 30,000 cells per well and 
cultured without medium exchange for 4, 24, and 72 hours. At the end of the incubation 
period, the cell viability was determined with the Cell Titer 96AQueous One Solution 
Cell Proliferation Assay (MTS assay, Promega Corp.). Each 60 µL of MTS solution was 
added into each well of the 48-well plate, containing the samples in 300 µL of culture 
medium. Following an incubation period of 2 hours with 5% CO2 at 37°C, 100 µL of 
solution in each well of the 48-well plate was transferred into the 96-well assay plates and 
the light absorbance at 490 nm was recorded using a micro-plate reader (Molecular 
Device Vmax kinetic). The background absorbance at 490 nm was corrected by 
subtracting the average absorbance of the control wells without cells from each well to 
estimate viable cellular activity.   
 
4.3.6.2  In vitro Anti-Tumor Activity - Indirect Cell Culture 
 
 The effect of the Ch/EA composite films on cell viability was investigated via 
indirect cell culture using BD BioCoatTM Control Cell Culture inserts (12-well formats). 
This experiment was to evaluate cell response to the composite films through cell culture 
media. The insert contains a 0.45 µm pore size PET membrane which allows the culture 
medium only permeable to the membrane. This experimental design is to observe cell 
response to the released ellagic acid from the composite films into cell culture media. The 
bottom of each well plate was coated with 700 µL of a chitosan solution or a chitosan 
solution containing 1% (w/v) of ellagic acid (Ch/EA1) and dried at room temperature 
followed by rinsing with PBS (pH 7.4) twice and then dried again. 1.7 mL of the cell 
culture medium was added into each well of the 12-well plate with inserts, which were 
allowed to hydrate for 2 hours at 37°C. The cancer cells were then seeded at a density of 
60,000 cells per well on the upper chamber with 0.3 mL of culture medium. After the 
incubation for 4, 24, and 72 hours, the number of viable cells was determined using the 
Cell Titer 96AQueous One Solution according to the manufacturer’s instructions. 
 
 
4.3.7 Western Blot 
 
 To determine whether the levels of p53 had changed after treatment, rat C6 
glioma cells were treated with the Ch/EA1 for western blot analysis. This study was to 
investigate the expression of apoptosis-related proteins in brain cancer cells. After cell 
collection, treated or untreated cells were lysed with 80 µL of lysis buffer (1% Triton X-
100) on ice and then 4 µL of protease inhibitors were added to lysis buffer for 15 min. 
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Cell lysates were clarified by centrifugation at 13,200 rpm for 5min. The supernatant was 
transferred to a new tube and the remaining pellets were discarded. The samples were 
mixed with 25 µL of a loading buffer (4X Laemmli buffer) to denature proteins and 
boiled at 90℃ for 5 min. To separate proteins according to their molecular weights, 
molecular weight markers as a standard (4 µL per mini-gel well) and equivalent amounts 
of samples were loaded (40 µL per mini-gel well) into the bottom of each well of a gel 
(10% SDS-PAGE) with a running buffer (a standard migration buffer) by a micro-pipetter 
fitted with a long narrow tip.  
 
 Electrophoresis was started at 80 V for 90 min and then at 100 V for 1hour. 
When the dye molecule reaches the bottom of the gel, the power was turned off. To 
transfer protein from the gel to a membrane in an electrical field, the membrane was 
placed next to the gel. The two were sandwiched between absorbent materials, and the 
sandwich was clamped between solid supports to maintain tight contact between the gel 
and membrane. The sandwich was submerged in a transfer buffer to which an electrical 
field (40 V) was applied overnight. The negatively-charged proteins traveled towards the 
positively-charged electrode, but the membrane stopped them. The membrane was 
incubated in a blocking solution which contains 5% milk in 100 mL of 0.05% PBST by 
shaking at room temperature for 30 min. The membrane was then incubated with a 
primary antibody which was p53 mouse mAb (Cell Signaling Technology, 1:500 dilution) 
in a blocking solution at 4℃ overnight. Integrin β -1 was used as an internal control. The 
membrane was washed with 0.05% PBST 3 times and then incubated with a secondary 
antibody which was HRP conjugated anti-mouse IgG at a dilution of 1:40,000 for p53 or 
Integrin β-1 at room temperature for 30 min. The membrane was then washed with 0.05% 
PBST 3 times, after which proteins were detected using enhanced luminal reagents for 1 
min. 
 
 
4.3.8 Caspase-3 Activation 
 
 In order to investigate apoptotic cell death in response to Ch/EA composite films, 
caspase-3 activity was measured by ApoAlert caspase-3 assay kit from Clontech (Palo 
Alto, CA). Several studies have shown that caspase-3 activity is increased through a 
protease cascade during apoptosis in the early stage. Following treatment with the 
chitosan film for 6 hours and the Ch/EA1 for 2 hours or 6 hours, cells were trypsinized, 
washed twice in PBS, and then aliquoted at 2.5 × 106 cells per test, after which samples 
were centrifuged at 1,450 rpm for 5 min. After resuspending in 50 μL of chilled cell lysis 
buffer, cells were incubated on ice for 10 min. Cell lysates were centrifuged in a 
microcentrifuge at maximum speed (66,000 rpm) for 10 min to precipitate cellular debris, 
and then the supernatants were transferred into new microcentrifuge tubes. 50 μL of 2X 
reaction buffer containing DTT (1:100 dilution) was added to each supernatant, after 
which 5 μL of caspase-3 substrate (DEVD-p-nitroanilide, 1mM) was added to each tube. 
Samples were incubated at 37℃ for 1  hour and transferred to a 96-well plate for a plate-
reading in a micro-plate reader at 405 nm (Molecular Device Vmax kinetic) according to 
the manufacturer’s instructions provided with the assay kit. 
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4.3.9 In vitro Angiogenesis Assay 
 
 To evaluate the ability of endothelial cells to form tube-like structures after 
treatment, in vitro angiogenesis assay was performed with a gel of basement membrane 
(Chemicon International, Inc., Temecula, CA). A gel matrix consisted of laminin, 
collagen type IV, heparan sulfate, proteoglycans, and entactin. It also contained various 
growth factors (TGF-β, FGF) and proteolytic enzymes (plasminogen, tPA, MMPs) for 
maximal tube-formation. This assay was used to monitor the extent of tube assembly in 
human umbilical vein cells (HUVEC). To prepare the gel matrix, 100 μL of 10 X diluent 
buffer was added to 900 μL of ECMatrixTM solution in a sterile microfuge tube on ice to 
avoid solidification. After preparing the gel matrix, 50 μL of solution was transferred to 
each pre-cooled 96-well tissue culture plate and incubated at 37℃ for one hour to allow 
the matrix solution to solidify. The wells were then incubated for 8 hours at 37℃ with 
HUVEC cells (1×104 cells/well). The HUVEC were pre-cultured in the absence (control) 
or presence of the films (chitosan film or Ch/EA1) for 1 day before they were transferred 
into the gel matrix. The tube formation was examined microscopically using an inverted 
bright field (BF) microscope (Nikon ECLIPSE TE-2000U) and the images (100 X) were 
processed using MetaVue software. 
 
 
4.3.10 In vivo Anti-Tumor Activity     
 
 Female nude mice, 8-10 weeks of age and weighing 24 g to 30 g, were obtained 
from Charles River Laboratories, Inc. (Wilmington, MA, USA). A total of 15 female nude 
mice were used to evaluate the anti-tumor activity and toxicity of Ch/EA composite films, 
with five mice per group. All mice were housed in standard facilities with not more than 
three mice per cage and were given free access to water and food before treatments were 
initiated. Each mouse was inoculated subcutaneously with 4 × 106 cells in 200 µl of PBS 
of GFP (green fluorescent protein) tagged C6 rat glioma in the right flank. Each animal 
was weighed on the day of tumor injection. Each mouse was imaged and its tumor 
volume was measured using a caliper, an ultrasound machine (Philips HDI 5000), and 
Fluorescence Reflectance Imaging (FRI) system. Animals were anesthetized with an 
isoflurane/oxygen inhalation mixture during imaging procedures. Tumor volume was 
calculated according to the following formula: tumor volume (mm3) = (major axis) × 
(minor axis) 2 × 0.52 [Li 2004]. The major axis is the longest diameter of the tumor and 
the minor axis is the maximal line drawn perpendicular to the major axis [Kim 2007, 
Schwartz 2000, 2006].  
 
 Treatment was initiated by implanting either a chitosan film or Ch/EA20 film 
subcutaneously on the fifth day after tumor inoculation. In this study, higher 
concentration of ellagic acid (20 % (w/v)) was employed to effectively treat a tumor 
tissue because anti-tumor effect of the composite film depended on concentration of 
ellagic acid. The tumor was allowed to establish until the area was approximately 50-90 
mm2 on day 5 post implantation as measured by the product of two orthogonal diameters 
using a caliper. At this point, the tumors were generally small and visually detectable. 
This time point was chosen in order to treat the primary tumors at an early stage as well 
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as mimic treatment of the tumor residues following surgical resection. For the tumor 
control group, tumors were left untreated. For the two surgical intervention groups, after 
an incision was made around a tumor site with a scalpel, a chitosan film or a Ch/EA20 
was inserted beneath the tumor site and then the skin was sutured. After the treatments, 
all mice were caged individually under veterinary care and supervision. Animals were 
weighed and imaged every 2 days for signs of tumor growth and sacrificed if their body 
weight decreased by 10% of the starting weight or if the tumor size reached 2 cm in a 
diameter. Experimental data were expressed as the tumor volume change for anti-tumor 
effect of treatment and weight loss for toxicity.  
 
 The histology study was performed to examine the tumor cell population and the 
acute toxicity at the implantation site. Animals were euthanized after 21 days of 
observation and then tumors were retrieved along with adjacent tissue and fixed in 10% 
neutral buffered formalin before histology analysis. After fixation, tissue samples were 
embedded in paraffin. The paraffin embedded tissues were sectioned, deparaffinized with 
xylene, and then stained with hematoxylin and eosin for microscopic analysis. All of the 
animal experiments were approved by the Animal Welfare and Ethics Committee of the 
University of Tennessee Health Science Center. 
 
 
4.3.11 Statistical Analysis 
 
 All data are presented as mean ± standard deviation. Significant differences in 
release profile, degradation rate, cell activity, and tumor volume were analyzed by one-
way ANOVA test. The differences in groups and experimental time points were 
considered significant if p<0.05. 
 
 
4.4 Results 
 
 
4.4.1 In vitro Release Studies  
 
 In order to investigate the ellagic acid release from the composite films under in 
vitro conditions, the cumulative amount of ellagic acid in the medium was measured as a 
function of time. Figure 4.1 shows the resulting release profiles of the ellagic acid from 
the composite films. As shown in Figure 4.1a, the initial drug loading did not affect the 
release rate for 2 weeks, but significant difference was observed between the films 
containing the higher ellagic acid loading (Ch/EA20) and lower ellagic acid loadings 
(Ch/EA0.05, Ch/EA0.1 and Ch/EA0.5) at the 3 week incubation periods (p<0.05). It was 
also observed that the Ch/EA composite films exhibited a sustained slow release of 
ellagic acid.  
 
 In addition, another release profile of ellagic acid was performed in the presence 
of lysozyme to evaluate the effect of lysozyme on the release rate of ellagic acid. As 
shown in Figure 4.1b, the cumulative amount of the ellagic acid released from the films  
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Figure 4.1 In vitro cumulative amount of the ellagic acid released from the Ch/EA 
composite films. (a) absence of lysozyme and (b) presence of lysozyme (a and b are 
different in scale). The cumulative amount of the released ellagic acid was determined as 
a function of time by a UV spectrophotometer at 260 nm. Each value represents the mean 
± SD (n = 3 per each group). 
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in the presence of lysozymes was significantly higher than the absence of lysozymes. 
There was a significant difference between the Ch/EA20 and the others after 1-week 
incubation due to initial loading difference (p<0.05). This result demonstrated that the 
presence of lysozyme could increase the release of the ellagic acid from the Ch/EA 
composite films. It is worth noting that both release profiles of the ellagic acid from the 
films in the absence and presence of lysozyme did not show an initial burst effect but 
exhibited a sustained slow release. 
 
 
4.4.2 In vitro Enzymatic Degradation 
 
 To determine the degradation behavior of the Ch/EA composite films, the 
amounts of enzymatic-hydrolyzed films were measured by ninhydrin assay. Lysozyme 
can interact with chitosan films in an acidic condition around pH 5-6 and induce 
enzymatic degradation of samples. Figure 4.2a shows the degradation rates of the Ch/EA 
composite films with the same total weight for 3 weeks in lysozyme medium. The results 
showed significant increases in free amino groups corresponding to N-glucosamine from 
all the groups after 3 weeks incubation compared with 1 day incubation (p<0.05). This 
result indicates a continuous degradation of the films within the experimental period. In 
addition, the films containing lower concentration of ellagic acid (Ch, Ch/EA0.05, and 
Ch/EA0.1) exhibited significantly (p<0.05) higher enzymatic-degradation rates than the 
chitosan films containing higher concentration of ellagic acid (Ch/EA0.5, Ch/EA1, and 
Ch/EA20). This result demonstrated that the composite films containing higher weight 
percentage of chitosan released more free amino groups into the medium, indicating 
higher degradation rate.  
 
 Figure 4.2b shows the degradation rates of the Ch/EA composite films containing 
the same weight percentage of chitosan but different weight percentage of ellagic acid. 
There were significant increases in free amino groups from all the composite films after 3 
weeks incubation compared with 1 day incubation (p<0.05). This result also 
demonstrated that different concentrations of ellagic acid incorporated into chitosan films 
influenced degradation rates of the composite films even though the weight percentage of 
chitosan was same in all groups. The composite films containing higher concentration of 
ellagic acid (Ch/EA0.5, Ch/EA1, and Ch/EA20) exhibited lower degradation rates 
compared with lower concentration of ellagic acid (Chitosan, Ch/EA0.05, and Ch/EA0.1). 
This result suggested that the degradation rate of the Ch/EA composite films was affected 
by the weight percentage of chitosan and concentration of ellagic acid. This study showed 
that the Ch/EA composite films are enzymatically biodegradable, corresponding to 
interactions between chitosan and ellagic acid.  
 
 
4.4.3 Cell Viability - Direct Contact       
 
 Anti-proliferative effect of the Ch/EA composite films on human U87 
glioblastoma and rat C6 glioma cells was investigated by MTS assay. As shown in Figure 
4.3, there were significant increases in viability of U87 glioblastoma and C6 glioma cells  
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Figure 4.2 In vitro enzymatic degradation of the Ch/EA composite films. (a) Same initial 
total weight and (b) Same initial chitosan weight. The amount of free amino groups 
corresponding to N-glucosamine was determined as a function of time by a ninhydrin 
assay at 550 nm. Each value represents the mean ± SD (n = 3 per each group). 
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Figure 4.3 Viability of (a) human U87 glioblastoma and (b) rat C6 glioma via direct 
contact culture by MTS assay. The cells were cultured directly on each sample at a 
density of 30,000 cells per well without changing medium for 4, 24, and 72 hours. The 
absorbance is expressed as a measure of the cell viability on the chitosan coatings with 
varying concentration of the ellagic acid for 3 days incubation. The initial cell density 
was 30,000 cells per well. Each value represents the mean ± SD (n = 4 per each group). * 
denotes significantly different cell viability compared with the chitosan film, Ch/EA0.05, 
and Ch/EA0.1 at 4, 24, and 72 hours of the incubation (p<0.05). 
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on the chitosan film and Ch/EA0.05 after 72 hours incubation compared with 4 hours 
incubation (p<0.05). However, the viability of the U87 cells was slightly decreased when 
treated with the Ch/EA0.1 for 72 hours incubation compared with 4 hours (Figure 4.3a), 
but no significant change was observed (p=0.17). As shown in Figure 4.3b, a significant 
increase in the viability of C6 glioma cells on the Ch/EA0.1 was observed after 72 hours 
compared to 4 and 24 hours incubation (p<0.05). This result suggested that there was no 
inhibitory effect of the Ch/EA0.1 on the survival and growth of cancer cells. 
 
 However, the treatment by the Ch/EA0.5 and Ch/EA1 induced significant 
decreases in viabilities of the both cancer cells within few hours compared with the other 
treatments (p<0.05), indicating anti-cancer effects as shown in Figure 4.3a and b. This 
result suggested that Ch/EA composite films could inhibit the growth of cancer cells in an 
ellagic acid concentration dependent manner.  
 
 Figure 4.4 and 4.5 display the morphological changes of the U87 glioblastoma 
and C6 glioma cells on the chitosan film, Ch/EA0.1, and Ch/EA1 at 1 and 3 days 
incubation. After 1 day incubation, the U87 glioblastoma cells aggregated and were 
viable on the chitosan film and Ch/EA0.1 as shown in Figure 4.4a and c. This observation 
indicated that cancer cells could not proliferate well due to initial inhibitory effect of 
films. However, the U87 glioblastoma cells did not aggregate and lost their viability on 
the Ch/EA1 (Figure 4.4e).  
 
 After 3 days incubation, the U87 glioblastoma cells spread and proliferated on 
the chitosan film (Figure 4.4b) while they showed bigger aggregation in size on 
Ch/EA0.1 (Figure 4.4d). However, a few viable U87 glioblastoma cells were shown on 
the Ch/EA1 (Figure 4.4f). Similarly, the C6 glioma cells initially aggregated and then 
spread on the chitosan film and Ch/EA0.1 after 3 days incubation as shown in Figure 
4.5a-d, indicating the growth and proliferation of the glioma cells. However, the C6 
glioma cells could not survive and grow on the Ch/EA1 as shown in Figure 4.5e and f. 
 
 
4.4.4 Cell Viability - Indirect Contact   
 
 The indirect contact culture was used to evaluate the effect of the ellagic acid 
released from the Ch/EA1 on viability of U87 glioblastoma and C6 glioma cells for 4, 24, 
and 72 hours incubation. As shown in Figure 4.6, both cancer cell lines significantly 
proliferated in the absence of direct contact after 72 hours incubation compared to 4 
hours (p<0.05). The Ch/EA1 did not affect growth and proliferation of cancer cells 
through the indirect cell culture for 3 days incubation periods. This result indicated that 
the growth of U87 glioblastoma and C6 glioma cells were significantly affected by close 
contact of the Ch/EA composite film in an ellagic acid concentration dependent manner. 
Therefore, anti-tumor effect of the composite film might be localized at the targeted 
tissue area due to slow release of ellagic acid into surrounding area. However, there was 
significant difference between chitosan film and Ch/EA1 at 3 days incubation (p<0.05). 
This result indicated the released amount of ellagic acid from Ch/EA 1 influenced slowly 
both cancer cells for 3 days incubation. 
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Figure 4.4 Fluorescent images of GFP tagged human U87 glioblastoma. (a) chitosan film 
for 1 day; (b) chitosan film for 3 days; (c) Ch/EA0.1 for 1day; (d) Ch/EA0.1 for 3 days; 
(e) Ch/EA1 for 1day; (f) Ch/EA1 for 3 days. The initial cell density was 30,000cells per 
well. (MAG = ×100). These fluorescent images were generated by pseudo-color using 
MetaVue software after having been taken using a microscope (Nikon ECLIPSE TE-
2000U). 
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Figure 4.5 Fluorescent images of GFP tagged rat C6 glioma. (a) chitosan film for 1 day; 
(b) chitosan film for 3 days; (c) Ch/EA0.1 for 1day; (d) Ch/EA0.1 for 3 days; (e) Ch/EA1 
for 1day; (f) Ch/EA1 for 3 days. The initial cell density was 30,000cells per well. (MAG 
= ×100). These fluorescent images were generated by pseudo-color using MetaVue 
software after having been taken using a microscope (Nikon ECLIPSE TE-2000U). 
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Figure 4.6 Viability of (a) human U87 glioblastomas and (b) rat C6 gliomas via indirect 
contact culture by MTS assay. The cells seeded onto the permeable PET membrane were 
affected by the released ellagic acid into the culture medium. The absorbance is an 
indicator of the viability of the cells on the Ch/EA1 for 4, 24, and 72 hours incubation. * 
denotes significantly different cell viability compared with 4 hours incubation (p<0.05). 
** denotes significant difference compared with the chitosan film at 3 days incubation 
(p<0.05). Each value represents the mean ± SD (n = 3 per each group). 
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4.4.5 Western Blot Analysis for p53 
 
 The tumor suppressor protein p53 plays an important role in regulating survival 
and death of cancer cells. In response to some factors such as DNA damage, the level of 
p53 protein rises and induces cell cycle arrest or apoptosis. In order to investigate the 
mechanism by which the Ch/EA composite films inhibit cancer cell growth, the level of 
p53 in rat C6 glioma cells was examined after treatments. As shown in Figure 4.7, the 
p53 protein became detectable in rat C6 glioma cells after a treatment with the Ch/EA1 
while it did not appear to the untreated cells. This result demonstrated the Ch/EA 
composite films could induce the accumulation of the tumor suppressor protein p53, 
which likely preceded an induction of apoptosis. 
 
 
4.4.6 Caspase-3 Activation     
 
 Caspase-3 is an active cell death protease and activated in the execution phase of 
cell apoptosis. In order to identify whether the Ch/EA composite film induce apoptotic 
cell death, the effect of treatments (chitosan film or Ch/EA1) on caspase-3 activation was 
investigated in the U87 human glioblastoma and C6 rat glioma cells.  
 
 As shown in Figure 4.8, caspase-3 activation was significantly increased when 
both cancer cell lines were treated with the Ch/EA1 for 6 hours (p<0.05), followed by the 
Ch/EA1 for 2 hours (p<0.05) compared with an untreated group. This result indicated that 
caspase-3 activation was dependent on the time of treatment. There were significant 
increases in caspase-3 activation of both cancer cell lines by the treatment of the chitosan 
film compared with the untreated group (p<0.05). This result indicated that the chitosan 
film has an ability to influence the growth of cancer cells. However, the effect of the 
chitosan film on the caspase-3 activation was significantly lower compared with that of 
the Ch/EA1. This finding was consistent with the result of the cell viability measured by 
MTS assay shown in Figure 4.3, and suggested that Ch/EA composite films could induce 
apoptotic cell death within a few hours of interaction via the caspase-3 activation. 
 
 
4.4.7 In vitro Angiogenesis Assay 
 
 Tube formation is a multi-step process involving adhesion, migration, 
differentiation and growth of cells. This study was to examine the ability of the Ch/EA 
composite film to inhibit the growth of HUVEC using a widely used angiogenesis assay. 
Figure 4.9 shows the tube formations of the HUVEC in response to the different 
treatments. The HUVEC were allowed to grow and differentiate in the gel matrix for 8 
hours after treatments. As shown in Figure 4.9a and b, when the HUVEC were cultured 
without treatment or treated with a chitosan film, the cells aligned themselves end to end, 
elongated and formed interconnected networks of cells because the matrix components 
influenced the behavior of cells. However, when the HUVEC were treated with the 
Ch/EA1 for 1 day (Figure 4.9c), they did not change their morphology and tube 
formation was not observed.  
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Figure 4.7 Western blot analysis of the p53 protein levels in the rat C6 glioma cells. (a) 
untreated and (b) treated with the Ch/EA1 for 1 day. 
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Figure 4.8 Caspase-3 activity after treatment. (a) human U87 glioblastoma and (b) rat C6 
glioma cells (untreated; chitosan film for 6 hours; Ch/EA1 for 2 or 6 hours). * denotes 
significantly increased caspase-3 activity compared with the untreated and the chitosan 
film (p<0.05). ** denotes significantly increased caspase-3 activity compared with 2 
hours incubation (p<0.05). Each value represents the mean ± SD (n = 3 per group). 
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Figure 4.9 In vitro angiogenesis assay to investigate the morphological differentiation of 
HUVEC into capillary-like structures. Cells were (a) untreated; (b) treated with chitosan 
film for 1 day; (c) Ch/EA1 for 1 day. The HUVEC (10,000 cells per well) were cultured 
on a gel matrix for 8 hours after each treatment. The endothelial network formation was 
observed and photographed under a phase contrast inverted microscope (Nikon ECLIPSE 
TE-2000U).  
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 This was probably because the cells lost their viability after treatment with the 
Ch/EA1 for 1 day. This result demonstrated that the chitosan/ellagic acid composite film 
(Ch/EA1) was effective at inhibiting morphological differentiation of the HUVEC, 
indicating the effect of the Ch/EA composite film on suppressing angiogenesis. 
 
 
4.4.8 In vivo Anti-Tumor Activity    
 
 In order to study the in vivo anti-tumor effect of Ch/EA composite films, the 
primary tumors were treated at an early stage. The treatment was initiated by implanting 
films (chitosan or Ch/EA20) subcutaneously on the fifth day after tumor inoculation. 
Tumor growth was evaluated by measuring tumor volume using a caliper, an ultrasound 
machine, and an optical imaging system every two days after treatment. Tumor growth 
was measured in real-time without sacrificing animals. All size measurements were 
determined using the largest diameter of the tumor tissue and its largest perpendicular 
diameter (Figure 4.10). 
 
 The result demonstrated that the Ch/EA20 group significantly inhibited the 
growth of tumor tissue compared with the untreated group and chitosan control group 
over 3 weeks observation (p<0.05). The different measurements showed different volume 
increases in the tumor tissues with time, but all the results indicated that Ch/EA20 group 
significantly delayed the growth rate of the tumor tissue compared with the other groups. 
Using a caliper measurement as shown in Figure 4.11, the difference of the tumor volume 
became statistically significant between the Ch/EA20 and untreated group from day 9 
after tumor inoculation (p<0.05). 
 
 The difference was statistically significant between the Ch/EA20 and the 
chitosan group from day 15 after tumor inoculation (p<0.05). There was also a significant 
difference between the untreated and the chitosan group at day 11 and 13 after tumor 
inoculation (p<0.05). However, there was no significant difference between the untreated 
and the chitosan group at the end of an experiment period. 
 
 Using an ultrasound measurement as shown in Figure 4.10b, a cross sectional 
area of a tumor tissue was imaged, and the two largest perpendicular diameters were 
measured and calculated according to formula [Li 2004]. As shown in Figure 4.12a, there 
was a significant difference between the Ch/EA20 group and untreated group from day 9 
after tumor inoculation (p<0.05). The difference was statistically significant between the 
Ch/EA20 group and the chitosan group from day 9 after tumor inoculation (p<0.05). 
There was no significant difference between the untreated and the chitosan group during 
the experimental periods. Figure 4.12b shows the ultrasound scan images indicating 
different tumor volumes among groups. This result demonstrated that the Ch/EA20 film 
could significantly delay the growth rate of the glioma tumor compared with the other 
groups. 
 
 Using optical measurement as shown in Figure 4.10c, density differences of the 
tumor tissue was imaged using fluorescent emission.  
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Figure 4.10 The measure of tumor volume using (a) caliper; (b) ultrasound machine; (c) 
fluorescence reflectance imaging (FRI) system. Each mouse was inoculated 
subcutaneously with GFP tagged rat C6 glioma cells at the density of 4 × 106 cells in the 
right flank. The cross-product of the two largest perpendicular diameters was calculated: 
tumor volume (mm3) = (major axis) × (minor axis) 2 × 0.52. The major axis is the longest 
diameter of the tumor and the minor axis is the maximal line drawn perpendicular to the 
major axis. 
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Figure 4.11 In vivo anti-tumor efficacy comparisons using a caliper. The treatments were 
initiated on day 5 after tumor inoculation as a function of time. Untreated tumor-bearing 
group (closed diamond, n = 5), chitosan control group (closed triangle, n = 5), and 
Ch/EA20 experimental group (closed square, n = 5). 
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Figure 4.12 In vivo anti-tumor efficacy comparisons using an ultrasound machine. The 
effect of treatments on tumor growth was evaluated by (a) volume measurements; (b) 
ultrasound images. The treatments were initiated on day 5 after tumor inoculation as a 
function of time. Untreated tumor-bearing group (closed diamond, n = 5), chitosan 
control group (closed triangle, n = 5), and Ch/EA20 experimental group (closed square, n 
= 5) were compared. Ultrasound scan images show the nude mice with GFP tagged rat C6 
glioma on each right flank at the 5, 13, and 21 days after tumor inoculation. 
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Figure 4.12 (continued).  
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 Higher intensity of fluorescent emission represented higher tumor population. As 
shown in Figure 4.13a, there was a significant difference between the Ch/EA20 and the 
untreated group from day 9 after tumor inoculation (p<0.05). The difference was 
statistically significant between the Ch/EA20 and the chitosan group for day 15, 17, 19 
and 21 after tumor inoculation (p<0.05). There was also a significant difference between 
the untreated and the chitosan group at day 9 and 11 after tumor inoculation (p<0.05). 
However, no significant difference in tumor growth was observed between the untreated 
group and the chitosan group for day 15, 17, 19 and 21 after tumor inoculation. The 
optical imaging clearly showed a smaller tumor volume in the Ch/EA20 group compared 
with those in the untreated and a chitosan film group (Figure 4.13b), indicating an 
effective suppression of the tumor growth in the Ch/EA20 group. 
 
 As shown in Figure 4.14, there was a significant difference (p<0.05) in weight 
loss between the Ch/EA20 and the other groups from day 5 to day 7 of the experiment. 
The mice treated with the Ch/EA20 films displayed higher weight loss at the first 1-2 
days after treatments compared with the other groups, but they had a weight curve similar 
to those of the other groups. Weight loss was less than 10% for all the groups, indicating 
no severe toxic side effects on animals during the period of experiments. 
 
 As shown in Figure 4.15 and 4.16, the efficacy of the local delivery of ellagic 
acid was confirmed by the histological analysis of tumors. For the tumor bearing group 
(untreated) and the chitosan group, the tumor cells were aggressive, invasive, and highly 
populated. Mostly, the center of tumors experienced necrosis (cell fragments and nuclear 
debris). For the Ch/EA20 group, it was observed that there were a decrease in tumor cell 
population and a formation of fibrous tissue surrounding the material. The mixture of a 
few inflammatory cells and necrotic cells was also found, indicating a sort of foreign-
body reaction. In tumor cell zone close to the material, tumor cells were not aggressive 
but less populated. The result demonstrated that the Ch/EA20 did not induce severe 
inflammatory response but reduced the population of invasive tumor cells around the 
Ch/EA20. 
 
 
4.5 Discussion 
 
 To optimize therapeutic efficacy, numerous drug delivery strategies have been 
explored in terms of efficacy and safety. Especially, for brain cancer, the blood-brain-
barrier (BBB) limits the access of therapeutic agents to brain tumor. In this regard, a local 
therapy combined with surgery provides a direct delivery of drugs into the brain, 
bypassing the BBB, thus improving efficacy. In the present study, Ch/EA composite films 
were studied to treat glioma tumors via a local delivery of ellagic acid.  
 
 One of the limitations of conventional drug delivery is an initial burst effect. 
Drug release of biodegradable systems is achieved by diffusion via pores in the polymer 
matrix and polymer degradation [Dash 1998, Gunatillake 2003, Tomihata 1997]. In this 
study, the in vitro release profile of the ellagic acid from the Ch/EA composite films 
clearly revealed a sustained slow release of ellagic acid both in the presence and absence  
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Figure 4.13 In vivo anti-tumor efficacy comparisons using an optical imaging system. The 
effect of treatments on tumor growth was evaluated by (a) volume measurements; (b) 
fluorescence images. The treatments were initiated on day 5 after tumor inoculation as a 
function of time. Untreated tumor-bearing group (closed diamond, n = 5), chitosan 
control group (closed triangle, n = 5), and Ch/EA20 experimental group (closed square, n 
= 5). Fluorescence images show the nude mice with GFP tagged rat C6 glioma on each 
right flank at the 5, 13, and 21 days after tumor inoculation. 
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Figure 4.13 (continued).  
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Figure 4.14 The percentage of weight loss of animals over time periods of treatments 
after tumor inoculation. Untreated tumor-bearing group (closed diamond, n=5); chitosan 
carrier control group (closed triangle, n=5), and Ch/EA20 experimental group (closed 
square, n=5). 
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Figure 4.15 Histological analysis of rat C6 gliomas stained with hematoxylin and eosin. 
The tumor tissue cross sections represents the untreated tumor-bearing group with (a) 
viable and active tumor cells; (b) necrotic area; and the chitosan control group with (c) 
active tumor cells; (d) necrotic area. The samples were retrieved along with adjacent 
tissue after completion of the experiment (on day 21 after tumor inoculation). (MAG = 
×200). 
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Figure 4.16. Histological analysis of rat C6 gliomas stained with hematoxylin and eosin. 
The tumor tissue cross sections of Ch/EA20 experimental group represent (a) the material 
zone including the formation of the fibrous tissue and dead cells and the tumor cell zone 
(×40); (b) the magnified material zone with a thin layer of fibrous tissue and dead cells 
(×200); (c) the magnified tumor cell zone close to the material (×200). The samples were 
retrieved along with adjacent tissue after completion of the experiment (on day 21 after 
tumor inoculation). 
 
 
 
 
 78 
of lysozyme. The presence of lysozyme could significantly accelerate the release of 
ellagic acid compared with the absence of lysozymes. The in vitro degradation study 
demonstrated that the enzymatic degradation rate of the Ch/EA composite films was 
ellagic acid-concentration dependent. The composite films with higher concentration of 
ellagic acid (Ch/EA0.5, Ch/EA1, and Ch/EA20) exhibited slower degradation rate 
compared with lower concentration of ellagic acid (Ch, Ch/EA0.05, and Ch/EA0.1). As 
discussed in chapter 3, ellagic acid was conjugated with chitosan polymer via covalent 
bonds or ionic forces and embedded into chitosan polymer network [Kim 2009]. 
Therefore, the degradation rate of Ch/EA composite films corresponds with interactions 
between chitosan and ellagic acid. 
 
 In the previous study of degradation behavior, two pH values of 6 and 7.4 were 
examined. The result showed that the higher degradation rate occurred around pH 6 in 
lysozyme-containing phosphate buffer solution compared with pH 7.4. In order to 
observe the differences among experimental groups in a timely manner, in this chapter, 
the phosphate buffer solution was prepared at pH 6. Chitosan is usually degraded via 
chitinase or lysozyme digestion. The fraction of N-acetylglucosamine (NAG) units in 
chitosan contributes to its enzymatic hydrolysis [Freier 2005]. The ellagic acid on the 
surface of composite film inhibited the binding of lysozyme to the NAG units on the 
chitosan chains and slowed the reactions lysozymes catalyze, thereby decreasing the 
enzymatic hydrolysis rate in chitosan films. It is well known that the degradation of 
chitosan films is dependent on the degree of deacetylation (DDA) and molecular weight 
[Muzzarelli 1997, Pangburn 1982, Ren 2005]. Chitosan films that are deacetylated more 
than 73 % showed a slow biodegradation rate [Khan 2002, Mi 2002]. Since a chitosan 
having a degree of deacetylation (more than 85 %) have been used, this characteristic of 
chitosan contributed to the slow release of ellagic acid. In addition to the low solubility of 
the chitosan carrier, ellagic acid is only slightly soluble in medium at pH 6.0. All the 
factors contribute to the sustained slow release rate of ellagic acid from films. In this 
regard, the release of ellagic acid from the composite films depends on characteristic of 
chitosan, fabrication methods, ellagic acid loadings, solubility, interactions between 
chitosan and ellagic acid, and medium (release environment) [Dash 1998].  
 
 This study investigated the viability of the human U87 glioblastomas and rat C6 
glioma cells and the corresponding cell morphological changes on the composite films. In 
the study of direct cell culture, the Ch/EA composite films showed anti-proliferative 
effect against cancer cells in an ellagic acid concentration-dependent manner. However, 
the cells in absence of direct contact with the composite films significantly proliferated. 
This is probably due to the slow release of the ellagic acid into the cell culture media as 
shown in the release study. These results clearly suggest that the Ch/EA composite films 
have a localized anti-proliferative effect on cancer cells. This localized effect was also 
verified in the cell morphological changes at the interface of the composite films in 
chapter 3 [Kim 2009].  
 
 Ellagic acid can induce apoptotic process via the intrinsic mitochondrial pathway 
[Khan 2007, Mertens-Talcott 2005, Narayanan 1999]. The p53, a tumor suppressor 
protein is an important key protein involved in this pathway. The p53 protein arrests cell 
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cycle and acts as pro-apoptotic signal. The p53 mediated activation of the pro-apoptotic 
proteins such as PUMA, NOXA, and BID induces the activation of caspases, leading to 
apoptosis [Bai 2006, Khan 2007]. In this study, p53 protein in the rat C6 gliomas and 
caspase-3 activation in the U87 human glioblastomas and the rat C6 gliomas were 
investigated. The results showed that the Ch/EA composite films induced the 
accumulation of the tumor suppressor protein p53 and increase caspase-3 activation. The 
findings of this study suggest the Ch/EA composite film is able to suppress cancer growth 
by inducing apoptosis. Therefore, the induction of apoptosis by the composite films can 
minimize inflammatory response causing the damage in the surrounding tissue. 
  
 The angiogenesis is an essential step in tumor growth. The formation of new 
blood vessels associated with tumor growth via angiogenesis is a complex process. 
Endothelial cells are able to aggregate to form capillary-like structures. Besides the 
apoptosis mechanism, this study examined the ability of Ch/EA composite films to inhibit 
the growth of HUVEC. In order to observe tube formation of endothelial cell, special gel 
membranes were used. These membranes are composed of laminin, collagen type IV, 
heparin sulfate, proteoglycans, entactin, and nidogen, and can accelerate the 
morphological differentiation of endothelial cells [Kubota 1988]. The endothelial cells on 
the basement membranes rapidly differentiate and start to form tubes within a few hours 
and complete by 1 day. This study demonstrated that a reconstituted gel membrane 
promoted morphological differentiation of the HUVEC into capillary-like structures 
when the cells were untreated or treated with the chitosan film. However, the HUVEC 
treated with Ch/EA1 could not grow, differentiate, and form tubes. This study indicated 
that even though the basement membrane provided the key ingredients in the induction of 
angiogenesis, the Ch/EA1 reduced the cell viability and suppressed angiogenesis. 
 
 Following the in vitro study, the in vivo anti-tumor activity and toxicity of the 
composite films were investigated using a mouse flank tumor model. To maximize the 
effect of this local delivery, the glioma tumors were treated at an early stage with films 
containing high concentrations of ellagic acid (Ch/EA20). Some studies [Au 2001, Bello 
2002, Giussani 2003] demonstrated that the most significant effect on animal survival and 
suppression of tumor growth was dependent on the time at which treatment was initiated. 
A preliminary animal study, in which the treatment group (Ch/EA10) was implanted on 
the eleventh day after tumor inoculation, demonstrated there was no significant difference 
between a control group and a treatment group. This result suggests the significant effect 
corresponds with initial treatment time and concentration of ellagic acid. Therefore, in 
this study, treatment was initiated on the fifth day after tumor inoculation. At this point, 
the tumors were small and visually detectable.  
 
 This animal study demonstrated that the Ch/EA20 group significantly inhibited 
tumor growth compared with the untreated tumor-bearing group and chitosan carrier 
control group. However, severe weight loss, an indicator of toxic side effect, was not 
observed in all the groups. In addition, the histological analysis also demonstrated the 
Ch/EA20 did not induce any severe toxic effect on its surrounding area but a formation of 
fibrous tissue and dead cells. The tumor cell zone close to the Ch/EA20 showed the 
population of the tumor cells which have lower density and tiny round shapes compared 
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with the untreated group and chitosan group. This indicates the tumor cells were affected 
by the release of ellagic acid. The high efficacy and low toxicity of the treatment are 
attributed to the slow and localized release of ellagic acid from the composite film. These 
results are very encouraging and will allow us to further investigate the naturally-based 
delivery systems to locally administer naturally-based therapeutics to treat tumors, 
thereby improving both the safety and efficacy of cancer treatment. 
 
 
4.6 Conclusion 
 
 This study showed the effect of a local delivery of ellagic acid against brain 
cancer in vitro and in vivo. The Ch/EA composite films showed a sustained slow release 
of ellagic acid without an initial burst effect. They were enzymatically degradable, 
indicated by at least a 5 times higher concentration of free amino groups at 3 weeks 
incubation compared with 1 day. The presence of lysozyme and concentration of ellagic 
acid influenced the release profile of ellagic acid from the films. These composite films 
were able to induce apoptotic cell death in an ellagic acid concentration dependent 
manner and inhibit the morphological differentiation of the HUVEC in vitro. The Ch/EA 
composite film also significantly suppressed glioma tumor growth in vivo. Tumor volume 
growth observed at 3 weeks was lower in the Ch/EA20 group compared to control groups 
as measured with a caliper, an ultrasound machine, and an optical imaging system by 9 
times, 3 times, and 7 times, respectively. This study demonstrated that the Ch/EA 
composite film can treat glioma cancer using anti-cancer properties of ellagic acid in a 
local site.  
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CHAPTER 5. DEVELOPMENT AND EVALUATION OF A CHITOSAN BASED 
INJECTABLE GEL FOR BRAIN CANCER TREATMENT  
 
 
5.1 Abstract 
 
 A chitosan based injectable gel has been developed for local delivery of ellagic 
acid. Chitosan delivery of ellagic acid inhibits growth of brain cancer cells. The 
chitosan/β-glycerophosphate solutions (Ch/β-GP) were prepared with different 
concentrations of β-GP and the ellagic acid was loaded to evaluate the anti-tumor effect 
of the gel on brain cancer cells (human U87 glioblastomas and rat C6 glioma cells). The 
properties of the Ch/β-GP gels were investigated regarding chemical structure, surface 
morphology, and viscoelasticity. In vitro ellagic acid release studies were performed by 
monitoring UV absorbance and enzymatic degradation rate was determined by increase in 
free amino groups of chitosan. Cell number and activity were monitored by the MTS 
assay. The liquid Ch/β-GP solution underwent thermal gelation at body temperature. The 
gelation temperature was dependent on the pH of the Ch/β-GP solution rather than 
concentration of β-GP. The Ch/β-GP gels were enzymatically degradable, showing the 
released free amino groups were at least 12 times higher at 3 weeks compared with 1 day. 
Ellagic acid release increased in the presence of lysozyme, indicated by at least a 2.5 
times higher concentration of ellagic acid than that in the absence of lysozyme. Dialysis 
of chitosan solution reduced the β-GP needed to reach pH 7.2, resulting in 4 times higher 
cell viability than undialyzed chitosan gel at 3 days culture. Viability of U87 cells and C6 
cells cultured on chitosan gels containing 1% (w/v) of ellagic acid were lower than the 
same cells on chitosan gels at 3 days incubation by 3.8 times and 6.5 times, respectively. 
 
 
5.2 Introduction 
 
 Conventional chemotherapy non-specifically distributes drugs to the whole body. 
Toxicity of the drug limits the maximum dose achievable within a tumor or leads to 
unacceptable side effects [Avgeropoulos 1999, Groothuis 2000, Jain 2001]. Due to these 
complications, implantable delivery systems have gained special attention to control the 
release of drugs and localize treatments in specific targeted sites. These local delivery 
systems provide the opportunity for improving both the efficacy and safety for cancer 
treatment [Ewend 1996, Olivi 2003, Walter 1994]. Toxic side effects attributed to high 
drug concentrations can be minimized because the drug is delivered locally, rather than 
systemically. However, these implantable delivery systems require surgery near the target 
sites, which leads to additional costs and surgical pains [Avgeropoulos 1999, Westphal 
2003].  
 
 In recent years, the injection of gel forming solutions has been considered a 
promising method to deliver drugs at target areas locally. Injectable hydrogels have 
several advantages over the common approach for drug delivery systems [Gutowska 2001, 
Hoemann 2005, Lee 2001, Molinaro 2002, Qu 1999, Roughley 2006, Ruel-Gariepy 2000, 
Ta 2008]. Their initial liquid formulation can flow easily and fill any target area shape. 
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The gel can include a variety of therapeutic agents including hydrophobic drugs, growth 
factors, and cells. The polymer formulation can be stored at room temperature or below 
before the administration. Above all, there is no requirement for a surgical procedure for 
implantation. A therapeutic agent is delivered close to the targeted site by a simple 
injection of a liquid formulation, which undergoes thermal gelation at body temperature.  
 
 Chitosan based materials have been used in the area of drug delivery for 
sustained release of therapeutic agents [Bae 2006, Berrada 2005, Ruel-Gariepy 2004, Ta 
2009]. Chitosan is an attractive biopolymer due to its biodegradability and 
biocompatibility. Recently, chitosan based injectable gels with various polyols such as 
glycerol, ethylene glycol, sorbitol, etc have gained significant attention because of their 
ability to deliver specific drugs at a target area [Back 1979, Chenite 2000, Iliescu 2008, 
Jarry 2002, Kokufuta 2005, Wu 2007]. These polyols maintain chitosan as a liquid. 
Polyols form a shield of water around chitosan chains in an acidic solution and maintain 
the solubility of chitosan at higher pH values at lower temperatures [Berger 2004, Jarry 
2002, Kokufuta 2005]. Especially, β-glycerophosphate (β-GP) has attracted a lot of 
attention in forming thermo-sensitive chitosan based gel delivery vehicles [Chenite 2001, 
Cho 2005, 2006, Crompton 2007, Hoemann 2007, Wu 2006].  
 
 Several interactions reported during the gelation process are the loss of 
electrostatic repulsion, hydrogen bonding, and increased hydrophobic interactions. The 
addition of disodium β-GP into chitosan solution increases the pH, thereby reducing the 
electrostatic repulsion between chitosan chains. This reaction, in turn, induces an increase 
in chitosan interchain hydrogen bonding. Raising the temperature strengthens the 
hydrophobic interactions between chitosan chains and induces gelation. The mechanism 
may be because the hydration water molecules hydrogen bonded to chitosan chains are 
released with increasing temperature. This would allow increased hydrophobic 
interactions between chitosan chains [Berger 2004, Cho 2005]. In order to form the gel 
network at body temperature within physiologically acceptable pH range, it is necessary 
to include high concentration of β-GP, which induces toxicity. To improve 
biocompatibility of this system, several researches have used low concentration of 
inorganic phosphate salts or added cross-linkers such as glyoxal and hydroxyethyl 
cellulose, which are responsible for the solidification of chitosan based hydrogels with 
low concentrations of β-GP [Crompton 2007, Hoemann 2007, Nair 2007, Roughley 2006].  
 
 In the present study, as shown in Figure 5.1, a novel method to produce a heat-
induced chitosan gel is described which minimizes β-GP toxicity. Acidic chitosan 
solution is dialyzed to prior to adding β-GP reducing the amount of β-GP needed which 
may lead to biocompatibility. To test the vehicle for drug delivery, ellagic acid is added to 
the chitosan solution. Ellagic acid shows anti-carcinogenic properties via cell cycle arrest, 
induction of apoptosis, and inhibition of tumor formation and growth. In the previous 
studies [Kim 2009], it was found that a chitosan film delivery system loaded with ellagic 
acid could induce apoptotic cancer cell death in an ellagic acid concentration dependent 
manner in vitro and in vivo. The objective of this study was to develop and characterize a 
thermo-sensitive Ch/β-GP gel and evaluate its anti-tumor effect on cancer cells (human 
U87 glioblastomas and rat C6 glioma cells) when loaded with ellagic acid in vitro. 
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                      (a)                       (b) 
 
 
Figure 5.1 Photograph showing the thermal gelation of the chitosan/β-GP solutions which 
were placed (a) at 5°C and (b) at 37°C for 30 minutes. 5 mL of chitosan solution 
contained 0.088 M of β-GP solution and the final pH was 7.23.  
 
 
5.3 Materials and Methods 
 
 
5.3.1 Materials 
 
 The chitosan was purchased from Sigma Aldrich in high molecular weight (≥ 310 
kDa) with an approximately 75% or greater degree of deacetylation. The ellagic acid and 
disodium β-GP (glycerol 2-phosphate disodium salt hydrate; cell culture grade) were also 
obtained from Sigma Aldrich. All other chemicals were reagent grade and used as 
received. Fetal bovine serum (FBS), Trypsin-EDTA, L-Glutamine, Antibiotic-
Antimycotic, Phosphate buffered saline (PBS), Ham's F12K medium, horse serum, and 
Dulbecco's Modified Eagle Medium (DMEM) were obtained from GibcoTM. The U87 
human glioblastoma, HS68 human newborn fibroblasts (passage 12) and C6 rat glioma 
cell lines were cultured as per American Type Culture Collection (ATCC) instructions. 
 
 
5.3.2 Preparation of the Chitosan /β-Glycerophosphate Solution: Ch/β-GP 
 
 A 1.5% (w/v) chitosan solution was prepared by stirring powdered chitosan in 
0.75% (v/v) aqueous acetic acid at room temperature overnight. The insoluble particles in 
the chitosan solution were removed by filtration. A 50% (w/v) β-GP solution was 
prepared in distilled water and sterilized using PES syringe filters with 0.22 µm pore size 
(MillexTM, MA) and stored at 4°C. 50 mL of chitosan solution was dialyzed at room 
temperature against 1 liter of distilled water for 6 days with daily changes of water (1 L) 
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in an 8 kDa cutoff dialysis membrane to reduce the acetic acid content. The final pH 
value of the chitosan solution was 6.17. The dialyzed chitosan solution was autoclaved at 
121°C for 20 minutes, cooled down to room temperature, and stored at 4°C. Sterilized, 
ice-cold β-GP solution (2.31 M) was added drop by drop to the chitosan solution under 
stirring conditions in an ice bath. The final concentration of β-GP in the chitosan solution 
ranged from 0.045 M to 0.660 M, and the final pH value ranged from 6.9 to 7.2. The 
dialyzed solutions were labeled DCh/β-GP. The DCh/β-GP solutions were placed into 50 
mL tubes, sealed, and stored at 4°C. In addition, undialyzed chitosan solutions (initial pH 
3.97) were prepared, mixed with a cold β-GP solution, and stored at 4°C. The final pH 
value of Ch/β-GP solution ranged from 6.9 to 7.2, and the final β-GP concentrations 
ranged from 1.027 M to 1.155 M. 
 
 
5.3.3 Preparation of the Chitosan/β-GP Solution Loaded with Ellagic Acid: DCh/β-
GP/EA 
 
 Ellagic acid solutions in distilled water (0.1 or 1% (w/v)) were prepared. The 
powdered ellagic acid was dissolved into distilled water by adding several drops of 0.1M 
NaOH, with constant stirring at room temperature overnight. The 1.5% (w/v) chitosan 
solutions were then mixed with the ellagic acid solutions at a chitosan to ellagic acid 
volume ratio of 1:1. The mixed chitosan/ellagic acid solutions were agitated at 40°C for 2 
hours and then neutralized over 3 or 4 days using a dialysis membrane. The 
chitosan/ellagic acid solutions were autoclaved at 121°C for 20 minutes, cooled down to 
room temperature, and stored at 4°C. Finally, they were mixed with the β-GP solution as 
described above. 
 
 
5.3.4 Characterization of the Chitosan/β-GP Gel 
 
5.3.4.1 FTIR Spectra 
 
 To characterize the chemical structure of the DCh/β-GP solution at 5°C and 37°C, 
FTIR spectra were obtained using a Nicolet FTIR Infrared Microscope coupled to a PC 
with analysis software. Samples were placed in a liquid cell assembled holder in the IR 
laser beam. All samples were chilled in an ice bath until they were incubated at 37°C. 
FTIR spectra of samples at 5°C and 37°C were obtained and compared. All spectra were 
recorded by transmittance mode (100 times scanning, 650-4000 cm-1). 
 
5.3.4.2 Scanning Electron Microscopy 
 
 The shapes and surface morphology of DCh/β-GP gel and DCh/β-GP/EA gel 
were observed by field emission scanning electron microscope (JEOL, JSM-633OF). The 
samples were prepared at 37°C for 3 hours and then dipped into distilled water at 37°C 
for 1 day. Next, they were lypholized overnight (Freezone, LABCONCO). The samples 
were fixed with conductive tape on a metal stub, coated with a carbon rod under vacuum, 
and examined at a 15 kV accelerating voltage with a working distance of 17 mm. 
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5.3.4.3 Rheological Analysis 
 
 Rheological measurement was performed with an AR 1000 rheometer (TA 
instruments) equipped with a coquette geometry, which required about 1 mL of the 
solution per sample. The top of geometry was filled with 1.5 mL of distilled water to 
create a humidified chamber. The chitosan solutions containing 1.027 M (final pH 6.97) 
or 1.155 M (final pH 7.17) of β-GP and the dialyzed chitosan solutions containing 0.045 
M (final pH 6.98) or 0.088 M (final pH 7.23) of β-GP were introduced to the rheometer. 
During the gelation process, the rheological properties of samples were measured with a 
temperature range of 10 to 50°C. The changes in the elastic (storage) modulus (G’) and 
the viscous (loss) modulus (G”) were recorded as function of temperature at a fixed 
frequency of 1 Hz. The phase lag (δ) and complex viscosity (η*) were taken to determine 
the gelation temperature at which the elastic modulus (G’) and the viscous modulus (G”) 
were equivalent in value (δ = 45°). The temperature was varied with a constant heating 
rate of 1 °C/min 
 
5.3.4.4  Gelation Time Determination 
 
 In order to determine the gelation time, the dialyzed chitosan solution containing 
0.045 M (final pH 6.98) or 0.088 M (final pH 7.23) of β-GP were prepared. The 5 mL of 
each sample was tested in glass vials (27 × 61 mm, Wheaton Glass). Gelation time was 
measured as a function of time at constant temperatures of 24°C, 37°C, 50°C, and 70°C 
in a water bath. The test tube inverting method was used to determine the gelation time 
[Nair 2007, Ta 2009]. The samples were incubated in a water bath at the predetermined 
temperatures, and time measurements were initiated. The flowability of the samples was 
observed every 30 seconds by tilting the tubes. The time at which flowing of the samples 
stopped was taken as the gelation time and the values were recorded. 
 
 
5.3.5 In vitro Release Studies 
 
 Ellagic acid release from the DCh/β-GP gel was quantified over time by an in 
vitro release assay. Dialyzed chitosan solutions containing 0.088 M of β-GP solution were 
loaded with 5.5 mg (DCh/β-GP/EA0.1) or 10 mg (DCh/β-GP/EA1) of ellagic acid. 1mL 
of each DCh/β-GP/EA solution was allowed to completely become a gel in an incubator 
at 37°C for 3 hours and placed in containers containing 6 mL of distilled water at 37°C. 
At designated time points (1, 3, 7, 14, and 21 days), 500 µL aliquots of the release 
medium were sampled and the same amount of fresh distilled water was added into the 
containers. In addition, release of ellagic acid in the presence of lysozyme (1 mg/mL) was 
also determined in order to examine the effect of an enzyme on the release profile. In the 
collected fractions, the cumulative amount of ellagic acid released as a function of time 
was determined by a UV spectrophotometer at 260 nm. 
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5.3.6 In vitro Enzymatic Degradation 
 
 Dialyzed chitosan solutions containing 0.088 M of β-GP solution were loaded 
with 5.5 mg (DCh/β-GP/EA0.1) or 10 mg (DCh/β-GP/EA1) of ellagic acid. 1mL of each 
DCh/β-GP/EA solution was allowed to become a gel in an incubator at 37°C for 3 hours 
and digested in 12-well plates containing phosphate buffer saline (PBS, pH 6) with 1 
mg/mL lysozyme (egg-white, Fisher Scientific, Fair Lawn, NJ) at 37°C. After the 
predetermined time points, 500 µL aliquots of medium from each sample were collected 
and the same amount of fresh lysozyme (1mg/mL) was added. A ninhydrin assay was 
performed to determine the amount of free amino groups in the incubation medium 
collected for 1, 3, 7, 14, and 21 days. After heating with ninhydrin at 95°C for 10 minutes, 
the light absorbance at 550 nm was recorded using a micro plate reader (Molecular 
Device Vmax kinetic). Glycine (Fisher Scientific, Fair Lawn, NJ) was used as an amino 
acid nitrogen standard at various known concentrations. Enzymatic degradation rate was 
determined by measuring the increase of N-glucosamine units in the incubation medium. 
 
 
5.3.7 Cell Culture 
 
 U87 human glioblastoma and HS68 human newborn fibroblast (passage 12) cell 
lines were grown and maintained in DMEM media with 10% FBS, 1% 
antibiotic/antimycotic mixture, 5 mL of L-glutamine (200 mM), and sodium pyruvate. 
The C6 rat glioma cell line was grown and maintained in Ham's F12K medium with 2.5% 
FBS, 15% horse serum, 2 mM L-glutamine adjusted to contain 1.5 g/L sodium 
bicarbonate, and 1% antibiotic/antimycotic mixture. The cells were cultured in an 
incubator supplied with 5% CO2 at 37°C. The culture medium was changed every 3 days. 
 
5.3.7.1 Cytotoxicity of β-GP Solution on Cell Culture 
 
 To investigate the toxic effect of the β-GP solution on cell culture, viability of 
human HS68 newborn fibroblasts was investigated with a MTS assay and the cell 
morphology was observed by microscope (Nikon ECLIPSE TE-2000-U). A β-GP solution 
(2.31 M) was prepared and sterilized using a PES syringe filter with 0.22 µm pore size 
(MillexTM, MA). A sterilized β-GP solution was added to cell culture media, and the 
final concentrations of β-GP in the media were 0, 45, 88, 131, 210, 385, 533, and 660 
mM (dilution of β-GP solution, originally 2.31 M). The cells were seeded on each well of 
48-well plates at a density of 30,000 cells per well in 300 µL of culture medium. The 
cells were cultured without medium exchange for 4, 24, and 72 hours. At the end of the 
incubation period, the cell viability was determined with the Cell Titer 96AQueous One 
Solution Cell Proliferation Assay (MTS assay, Promega Corp.). 60 µL of Cell Titer 
96AQueous One Solution was added into each well of the 48-well plates, containing the 
samples in 300 µL of culture medium. Following an incubation period of 2 hours at 37°C 
5% CO2, 100 µL of solution in each well of the 48-well plates was transferred into 96-
well assay plates and the light absorbance at 490 nm was recorded using a micro plate 
reader (Molecular Device Vmax kinetic). Prior to the MTS assay, the cell morphology 
was documented using an inverted bright field (BF) microscope (Nikon ECLIPSE TE-
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2000U) and processed using MetaVue software. 
 
5.3.7.2 Cytotoxicity of Chitosan/β-GP Delivery System on Cell Culture 
 
 To investigate the biological effect of chitosan/β-GP gels on cells, viability of 
human HS68 newborn fibroblasts was examined by a MTS assay, and cell morphology 
was observed by microscope (Nikon ECLIPSE TE-2000-U). Indirect culture via BD 
BioCoat™ Control Cell Culture inserts (12 well formats) was used to evaluate the effect 
of the chitosan/β-GP gels on cell viability through cell culture media. The insert contains 
a 0.45 micron pore size PET membrane with a thin layer of basement membrane which 
prevents cells from migrating through the membrane and allows only the culture medium 
through the PET membrane. Two different chitosan/β-GP gels were prepared. A dialyzed 
chitosan solution (pH 6.17) was mixed with 0.088 M of β-GP solution, while a chitosan 
solution (pH 3.96) was mixed with 1.155 M of β-GP solution. The final pH values of the 
solutions were 7.23 and 7.17, respectively. 1 mL of each chitosan/β-GP solution was 
placed into the bottom of well plates and incubated at 37°C for 1 hour prior to cell culture. 
1.7 mL of the cell culture medium was added into each well of the 12-well plates with 
inserts, which were allowed to hydrate for 2 hours at 37°C. The cells were then seeded at 
a density of 60,000 cells per well in the upper chamber with 0.3 mL of culture medium. 
After incubation for 4, 24, and 72 hours, the number of viable cells was determined using 
a Cell Titer 96AQueous One Solution assay according to the manufacturer’s instructions. 
Photomicrographs of cells were also documented during cell culture using a microscope 
and processed using MetaVue software. Cells were seeded on the chitosan/β-GP gels in 
24-well plates at a density of 60,000 cells per well and incubated with 500 µL of culture 
media for 3 days, after which the viable cells were stained with the calcein AM and then 
cell morphology was observed. 
 
 
5.3.8 In vitro Anti-Tumor Activity 
 
 To evaluate the anti-tumor effect of Ch/β-GP gels loaded with ellagic acid on the 
two cancer cell lines, the number of viable cells (human U87 glioblastoma and rat C6 
glioma) was measured by a MTS assay. Indirect culture via BD BioCoat™ Control Cell 
Culture inserts (12 well formats) was used to evaluate the anti-proliferative effect of 
Ch/β-GP/EA gels on cancer cells via cell culture media. The dialyzed chitosan solutions 
containing 0.088 M of β-GP solution were loaded with 5.5 mg (DCh/β-GP/EA0.1) or 10 
mg (DCh/β-GP/EA1) of ellagic acid. 1 mL of each DCh/β-GP/EA solution was placed 
into the bottom of each well plate and incubated for 1 hour prior to cell culture to become 
a gel. 1.7 mL of the cell culture medium was added into each well of the 12-well plate, 
and cells were then seeded at a density of 60,000 cells per well in the upper chamber with 
0.3 mL of the culture medium. After incubation for 4, 24, and 72 hours, the number of 
viable cells was determined using the Cell Titer 96AQueous One Solution assay as 
described above. 
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5.3.9 Statistical Analysis 
 
 All data are presented as mean ± standard deviation. Significant differences in 
release profile, degradation rate, and cell activity were analyzed by one-way ANOVA test. 
The differences in groups and experimental time points at any time were considered 
significant if p<0.05. 
 
 
5.4 Results 
 
 
5.4.1 FTIR Spectra 
 
 The FTIR spectra obtained from the chitosan/β-GP solution at 5°C and 37°C are 
shown in Figure 5.2. The protonation of the phosphate groups induced a reduction of the 
stretching of phosphate group (-PO42-) at 978 cm-1 with increasing temperature [Arai 
2001, Elzinga 2007]. The peaks of the diprotonated phosphate group (-H2PO4) at 37°C 
were shown at the range of 1146-1159 cm-1, indicating the nonprotonated phosphate 
group (-PO42-) accepted protons (H+) [Arai 2001, Elzinga 2007]. A broad band at 1206-
1250 cm-1 is assigned to the POH bending both in the chitosan/β-GP solution at 5°C and 
37°C [Elzinga 2007]. The intensity of the peaks in the range from 1620 to 1722 cm-1, 
which are attributed to the C=O stretching of amide I bonds of chitosan, were changed 
with increasing temperature. In addition, there were significant changes in spectrum 
shape at 1554, 1512, and 1427 cm-1, which are representative of the N-H bending 
vibrations of amide II bond of the chitosan with increasing temperature [Tien 2003, Wang 
2004]. 
 
 
5.4.2 Scanning Electron Microscopy 
 
 Figure 5.3 displays the SEM micrographs of the DCh/β-GP gels which were 
lyophilyzed overnight before the examination. The morphological structure of the DCh/β-
GP gel and the DCh/β-GP/EA gel was observed after dipping into distilled water for 1 
day. The DCh/β-GP gel (Figure 5.3a) showed irregular porous structure while the surface 
morphology of the DCh/β-GP/EA (Figure 5.3b) became rougher and more textured. 
 
 
5.4.3 Rheological Analysis 
 
 In order to determine the gelation temperature of the chitosan/β-GP solution, an 
AR 1000 rheometer (TA instruments) was used to measure the storage (elastic) modulus 
(G’), loss (viscous) modulus (G”), phase angle (δ) and complex viscosity (η*). With 
increasing temperature from 10°C to 50°C, all samples had a rapid increase of the storage 
modulus (G’), showing the phase transition of the chitosan/β-GP solution to the 
chitosan/β-GP gel around 37°C. The greater growth rate of the storage modulus (G’) 
compared with the loss modulus (G”) indicated that development of the gel structure  
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Figure 5.2 FTIR spectra of the chitosan/β-GP solution. (a) at 5°C and (b) 37°C. The 
chitosan solution contained 0.088 M of β-GP solution and its final pH was 7.23. 
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Figure 5.3 SEM micrographs on the surface of the chitosan/β-GP gels. (a) DCh/β-GP gel 
and (b) DCh/β-GP/EA gel. The samples were prepared by dipping chitosan/β-GP gels in 
distilled water at 37°C for 1 day, followed by lyophilization overnight (MAG = ×500). 
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contributed to the increase in elasticity. Figure 5.4 shows the effect of the final pH value 
of the DCh/β-GP solution on the gelation temperature. 
 
 The crossover of the storage modulus (G’) and the loss modulus (G”) moved to 
the left, indicating that the gelation temperature was lowered with increasing final pH of 
the gel forming solution as shown in Figure 5.4a and b. The phase angle (δ) of a dialyzed 
chitosan solution containing 0.045 M (final pH 6.98) of β-GP and 0.088 M (final pH 
7.23) of β-GP decreased gradually as the temperature increased. The phase angle reached 
45° where G’=G” at which the temperature was 33°C for pH 6.98 and 26°C for pH 7.23, 
respectively. This result indicated that the storage modulus (G’) began to increase at 
lower temperature with 0.088 M of β-GP (final pH 7.23) compared with 0.045 M of β-GP 
(final pH 6.98). The complex viscosity (η*) of a chitosan solution containing 0.088 M of 
β-GP also showed a sharp rise at lower temperature compared with 0.045 M of β-GP as 
shown in Figure 5.4c and d. 
 
 The gelation temperature of chitosan solutions containing high concentrations of 
β-GP (1.027 M and 1.155 M) was also investigated (Figure 5.5). Their final pH values 
were 6.97 and 7.17, respectively. The crossover point and 45° phase angle (where 
G’=G”) came at lower temperature of 34°C with 1.155 M of β-GP than the crossover 
point of 37℃ with 1.027 M of β-GP as shown in Figure 5.5a and b. In comparison with 
the chitosan solution containing lower concentrations of β-GP (0.045 M or 0.088 M), the 
phase angle (δ) of the chitosan solution containing higher concentrations of β-GP (1.027 
M or 1.155 M) decreased dramatically, rather than gradually. The results clearly 
demonstrated that chitosan solutions can undergo viscosity changes consistent with 
thermal gelation below body temperature after neutralization with either low 
concentrations of β-GP or high concentrations of β-GP. The gelation temperature was 
affected by the final pH of the chitosan/β-GP solution. 
 
 
5.4.4 Gelation Time Determination 
 
 In order to investigate the effect of the temperature on the gelation time, the 
fluidity of chitosan solutions were measured using the test tube inverting method. Figure 
5.6 shows that the gelation time decreases exponentially with increasing temperature. In 
addition to the changes in flow capabilities, the samples became opaque as the samples 
formed a gel. The chitosan solution at pH 7.23 containing 0.088 M of β-GP showed faster 
gelation time (150 seconds at 37°C) compared with the chitosan solution containing 
0.045 M of β-GP (330 seconds at 37°C). Gel formation times were also different at 24°C. 
At higher temperatures gel times became similar and were indistinguishable at 70°C. The 
shortest gel time observed in this assay was 60 seconds. 
 
 
5.4.5 In vitro Release Studies 
 
 In order to investigate the in vitro release rate of ellagic acid from the DCh/β-
GP/EA gels, the cumulative amount of ellagic acid released into the medium was 
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Figure 5.4 The gelation temperature of the dialyzed chitosan solution. (a) 0.045 M of β-
GP (pH 6.98); (b) 0.088 M of β-GP (pH 7.23) and the complex viscosity of the chitosan 
solution containing (c) 0.045 M of β-GP; (d) 0.088 M of β-GP. The storage modulus (G’) 
and the loss modulus (G”) of the chitosan/β-GP solution were evaluated with regard to 
the effect of the final pH on the gelation temperature. The effect of the final pH on the 
complex viscosity was also investigated as a function of temperature at ω = 6.28 rad/s 
with 1°C/min. The elastic modulus (G’) and the viscous modulus (G”) are equivalent in 
value at δ = 45°. 
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Figure 5.4 (continued).  
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Figure 5.5 The gelation temperature of the undialyzed chitosan solution. (a) 1.027 M of 
β-GP (pH 6.97); (b) 1.155 M of β-GP (pH 7.17) and the complex viscosity of the 
undialyzed chitosan solution containing (c) 1.027 M of β-GP; (d) 1.155 M of β-GP. The 
storage modulus (G’) and the loss modulus (G”) of the chitosan/β-GP solution were 
evaluated with regard to the effect of the final pH on the gelation temperature. The effect 
of the final pH on the complex viscosity was also investigated as a function of 
temperature at ω = 6.28 rad/s with 1°C/min. The elastic modulus (G’) and the viscous 
modulus (G”) are equivalent in value at δ = 45°. 
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Figure 5.5 (continued) 
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Figure 5.6 The gelation time of the DCh/β-GP solution as a function of the temperature. 
The DCh/β-GP solutions were prepared with different final pHs which were 6.98 and 
7.23, respectively. 
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measured as a function of time. Figure 5.7 shows the cumulative release profiles of 
ellagic acid from the DCh/β-GP/EA gels. 
 
 The initial drug loadings significantly affected the release rate of ellagic acid 
from the DCh/β-GP gels for 3 week incubation periods (p<0.05). The chitosan/β-GP gels 
containing higher ellagic acid loading (DCh/β-GP/EA1) released greater amounts of 
ellagic acid than lower ellagic acid loading (DCh/β-GP/EA0.1). There was a sustained 
slow release of ellagic acid from the chitosan/β-GP gels. 
 
 In addition, the effect of chitosan lytic enzymes on the release profiles of the 
chitosan/β-GP gels was evaluated in the presence of lysozyme. The cumulative amount of 
ellagic acid released from DCh/β-GP/EA gels in the presence of lysozyme was 
significantly higher than that in the absence of lysozyme (p<0.05). There was a 
significant difference (p<0.05) between DCh/β-GP/EA1 in the absence of lysozyme and 
DCh/β-GP/EA0.1 in the presence of lysozyme mainly due to initial loading difference. 
This result demonstrated that the release rate of ellagic acid from the DCh/β-GP gels was 
affected by initial loading and chitosan lytic enzymatic activity. It is worth noting that the 
release profiles in both absence and presence of lysozyme showed a sustained slow 
release, rather than an initial burst effect. 
 
 
5.4.6 In vitro Enzymatic Degradation 
 
 To determine the biodegradation rate of the DCh/β-GP gels in vitro, the amounts 
of enzymatic-hydrolyzed DCh/β-GP gels were measured by ninhydrin assay for chitosan 
vehicle alone and with 2 concentrations of EA described previously. Figure 5.8 shows the 
cumulative degradation rates of the DCh/β-GP gels for 3 weeks incubation in lysozyme 
medium. The results showed significant increases in free amino groups corresponding to 
N-glucosamine from all the groups after 3 weeks incubation compared with 1 day 
incubation (p<0.05), suggesting a continuous degradation of the DCh/β-GP gels. The 
DCh/β-GP/EA0.1 exhibited significantly lower enzymatic-degradation rates than the 
other groups at 7, 14, and 21 day (p<0.05). The higher initial loading of ellagic acid in the 
DCh/β-GP/EA1 led to a significantly higher degradation rate after 2 weeks incubation 
compared with the DCh/β-GP (p<0.05). 
 
 
5.4.7 Cytotoxicity of β-GP Solution 
 
 To evaluate the effect of the β-GP concentration on cell viability, human HS68 
newborn fibroblasts were cultured with media containing different concentrations of β-
GP solution. As shown in Figure 5.9, cell activity measured by a MTS assay decreased at 
210 mM β-GP or higher (p<0.05 for all time points). While there were significant 
increases in cell activity in culture media containing 0-131 mM of β-GP solution during 3 
days incubation (p<0.05), indicating no cytotoxic effect on cell survival and growth. 
There was an inverse relationship between β-GP and cell activity that became significant 
(p<0.05) at 88 mM of β-GP and 131 mM of β-GP after 3 days. This result suggests that 
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Figure 5.7 In vitro cumulative amount of the ellagic acid released from the DCh/β-GP/EA 
gels in the absence of lysozyme or in the presence of lysozyme. The cumulative amount 
of the released ellagic acid was determined as a function of time by a UV 
spectrophotometer at 260 nm. Each value represents the mean ± SD (n = 3 per each 
group). 
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Figure 5.8 In vitro cumulative enzymatic degradation of the DCh/β-GP gels. The amount 
of free amino groups corresponding to N-glucosamine was determined as a function of 
time by a ninhydrin assay at 550 nm: Each value represents the mean ± SD (n = 3 per 
each group). 
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Figure 5.9 Viability of HS68 human newborn fibroblasts via direct culture by the MTS 
assay. The cells were cultured at a density of 30,000 cells per well without changing 
medium for 4, 24, and 72 hours. The absorbance is expressed as a measure of the cell 
viability into culture medium containing different concentrations of β-GP solution for 3 
days incubation. * denotes significant increase in cell viability compared with 4 and 24 
hours incubation (p<0.05). ** denotes significantly different cell viability compared with 
0 mM, 45 mM, and 88 mM of β-GP at 3 days incubation (p<0.05). Each value represents 
the mean ± SD (n = 4 per each group). 
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cell viability was affected by β-GP solution in a dose-dependent manner. 
 
 
5.4.8 Cytotoxicity of Chitosan/β-GP Gel  
 
 To investigate the effect of the DCh/β-GP gels on human HS68 newborn 
fibroblasts via culture media, cytotoxicity evaluation was performed by a MTS assay and 
the cell morphology was observed by microscope (Nikon ECLIPSE TE-2000-U). Figure 
5.10 shows the photomicrographs of the calcein AM stained H68 fibroblasts. The result 
indicated that cells encapsulated inside gels were viable in a round shape (Figure 5.10a) 
while cells on the bottom of the well plate were spindle-like in shape and proliferated for 
3 days incubation (Figure 5.10b). In addition, cells which were encapsulated inside gels 
for 3 days were transferred to a new 24-well plate and cultured for 3 days. They changed 
their morphology and proliferated on the surface of the cell culture plate (Figure 5.10c). 
This result suggests that cells encapsulated inside gels were viable in their round shape 
until they reached the rigid flat surface on which cells were able to move, grow, and 
proliferate. 
 
 Lower β-GP concentration vehicles were desirable for biocompatibility. Dialysis 
of chitosan solution (DCh) before addition of β-GP reduced the amount of β-GP needed 
to achieve a pH of 7.2, which was physiologically acceptable and suitable for the gelation 
compared to undialyzed chitosan solution (Ch). The difference in biocompatibility is 
illustrated in Figure 5.11 which shows the cytotoxicity of the chitosan gels containing 
0.088 M of β-GP (DCh/β-GP; final pH 7.23) compared to 1.155 M of β-GP (Ch/β-GP; 
final pH 7.17). There were significant decreases in cell activity with 1.155 M o f β-GP 
after 4 hours compared with 24 hours and 3 days (p<0.05), indicating that 1.155 M of β-
GP is toxic.  
 
 However, cells in the chitosan gel containing 0.088 M of β-GP significantly 
increased cell activity after 3 days (p<0.05). This result was consistent with the 
photomicrographs shown in Figure 5.10, indicating that DCh/β-GP (0.088 M of β-GP) is 
not cytotoxic and allowed cell growth and proliferation. However, Ch/β-GP (1.155 M of 
β-GP) was toxic. Dialysis reduced the amount of β-GP needed to achieve pH 7.2. Dialysis 
was a key step to reduce the amount of β-GP needed to achieve a fluid, biocompatible 
vehicle that gels rapidly at body temperature. 
 
 
5.4.9 In vitro Anti-Tumor Activity of Chitosan/β-GP Gel 
 
 We investigated the anti-proliferative effect of the DCh/β-GP gels loaded with 
ellagic acid on human U87 glioblastoma and rat C6 glioma cells by a MTS assay. As 
shown in Figure 5.12a, there were significant increases in viability of U87 glioblastoma 
cultured with the Ch/β-GP gels after 72 hours incubation compared with 4 hours (p<0.05). 
However, the viability of the U87 cells was significantly decreased when they were 
cultured with the Ch/β-GP/EA0.1 or Ch/β-GP/EA1 for 72 hours incubation compared 
with 4 hours. There was a significant difference in the viability of the U87 cells between  
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                                   (c) 
 
 
Figure 5.10 Photomicrographs showing viability of HS68 human newborn fibroblasts via 
the direct culture on the DCh/β-GP gel. (a) cells encapsulated inside gel; (b) cells cultured 
outside gel; (c) cells in (a) were transferred to new 24-well plates and cultured for 3 days. 
The cells were cultured on the chitosan gels (0.088 M of β-GP) in 24-well plates at a 
density of 60,000 cells per well without changing medium for 3 days. The final pH of the 
chitosan/β-GP solution was 7.23. (MAG = ×100). 
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Figure 5.11 Viability of HS68 human newborn fibroblasts via indirect culture by the MTS 
assay. The cells cultured on the permeable PET membrane were affected by the chemicals 
released into the culture media from the chitosan gels. The chitosan/β-GP gels were 
prepared with 0.088 M of β-GP solution or 1.155 M of β-GP solution. The final pH of 
each chitosan/β-GP solution was 7.23 and 7.17, respectively. The initial cell density was 
60,000 cells per well and cells were cultured without changing medium for 4, 24, and 72 
hours. The absorbance is expressed as a measure of the cell viability via cell culture 
media for 3 days incubation. * denotes significantly different cell viability compared with 
the Ch/β-GP (1.155 M) for 3 days incubation (p<0.05). ** denotes significantly different 
cell viability compared with 4 and 24 hours incubation (p<0.05). Each value represents 
the mean ± SD (n = 3 per each group). 
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Figure 5.12 Viability of cancer cells via the indirect culture by the MTS assay. (a) human 
U87 glioblastoma; (b) rat C6 glioma. The cancer cells seeded onto the permeable PET 
membrane were affected by the ellagic acid released into the culture medium. The 
absorbance is an indicator of the viability of the cells for 4, 24, 72 hours incubation. Each 
value represents the mean ± SD (n = 3 per each group). 
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the Ch/β-GP/EA0.1 and the Ch/β-GP/EA1 for 3 days incubation (p<0.05), indicating the 
anti-tumor effect of the Ch/β-GP gel in an ellagic acid concentration dependent manner. 
 
 In addition, as shown in Figure 5.12b, a significant increase in the viability of C6 
glioma cells was observed when they were cultured with the Ch/β-GP gel or the Ch/β-
GP/EA0.1 for 72 hours compared with 4 and 24 hours incubation (p<0.05). This result 
suggests that there was no inhibitory effect of the Ch/β-GP/EA0.1 on the survival and 
growth of cells. However, there was a significant difference between the Ch/β-GP and the 
Ch/β-GP/EA0.1 after 24 hours incubation (p<0.05), indicating the effect of ellagic acid 
on cell growth. There was a significant decrease in the viability of the C6 glioma cells 
when cultured with the Ch/β-GP/EA1 after 72 hours compared with 4 and 24 hours 
incubation (p<0.05). This result demonstrated that the Ch/β-GP gel loaded with ellagic 
acid could inhibit the growth of cancer cells in an ellagic acid concentration dependent 
manner. 
 
 
5.5 Discussion 
 
 Recently, thermo-sensitive injectable systems have been studied to carry 
therapeutic agents, cells or molecules for local delivery [Hoemann 2005, Molinaro 2002, 
Ta 2008]. In particular, chitosan based injectable gels have notable potential as a drug 
carrier regarding controlled release and loading capacity [Bae 2006, Roughley 2006, 
Ruel-Gariepy 2000, 2004, Ta 2009, Tien 2004]. This study focused development and 
characterization of a thermo-sensitive Ch/β-GP gel regarding thermal gelation and 
biocompatibility. The anti-tumor effect of the Ch/β-GP gel on brain cancer cells were also 
evaluated according to different concentrations of ellagic acid. It was hypothesized that a 
heat-induced chitosan gel delivers anti-cancer activity of ellagic acid via a simple 
injection. 
 
 The gelation of a chitosan/β-GP solution is thermally induced via several types of 
interactions such as electrostatic attractions, hydrogen bonding, electrostatic repulsion, 
and hydrophobic effect [Chenite 2001, Cho 2005, Hoemann 2007, Wu 2006]. Chitosan 
polymer contains hydrogen bonding favoring groups such as hydroxyl (-OH), amine (-
NH2), amide (-NH-C) and carbonyl (-C=O) groups. It is positively charged in an acidic 
solution due to the protonation of the free amine groups, which causes electrostatic 
repulsion between chitosan molecules. When a weak base of disodium β-GP solution is 
added into an acidic chitosan solution, it increases pH and also induces electrostatic 
attractions between positively charged chitosan (NH3+) and negatively charged phosphate 
molecules (-HPO4- or -PO42-) of β-GP. It also reduces electrostatic repulsion between the 
chitosan chains due to charge neutralization by β-GP anion, which results in an increase 
in hydrogen bonding interactions along chitosan interchains [Cho 2005]. Generally, 
chitosan molecules in an acidic solution immediately form a hydrated precipitate by 
adding a strong base, such as NaOH, due to the reduced charge density along chitosan 
chains, which subsequently induces extensive hydrogen bonding and hydrophobic 
interactions between chains. This results in an inability to maintain chitosan molecules in 
a solution at physiologically acceptable pH [Berger 2004, Chenite 2001, Nair 2007].  
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 However, the glycerol molecules of β-GP form a shield of water around the 
chitosan molecules, maintain chitosan chains in their native form, and inhibit their 
aggregation at low temperature. Therefore, polyols and sugars have been used as 
stabilizer for protein or biopolymer to prevent structural changes [Back 1979, Chenite 
2000, Jarry 2002]. With increasing temperature, chitosan-chitosan interactions become 
dominant resulting in a phase transition from a liquid to a gel while hydrogen bonding 
interactions are reduced. After breaking of hydrogen bonding, phosphate groups function 
as a proton sink after chitosan chains release protons [Ta 2008]. The chitosan chains 
subsequently are brought close to precipitation resulting in the gelation of the chitosan/β-
GP formulation. Several studies have reported that phosphate groups of β-GP do not 
induce ionic crosslinking with the chitosan molecules [Chenite 2001, Cho 2005, Ta 2008]. 
Instead, the hydrophobic effect has been considered the main force to induce thermal 
gelation of the chitosan/β-GP system.  
 
 In the present study, the FTIR spectra revealed that the protonation of phosphate 
groups in the Ch/β-GP solution occurred with increasing temperature. This result 
indicates the transfer of protons (H+) in the Ch/β-GP solution during thermal gelation. As 
shown in Figure 5.2, the diprotonated phosphate (-H2PO4) groups appeared in the Ch/β-
GP at 37°C, suggesting the nonprotonated phosphate (-PO42-) ions accepted protons (H+) 
with increasing temperature [Arai 2001, Elzinga 2007]. As a result, there is a decrease in 
the protonation around the chitosan molecules, indicating decreased solubility of chitosan 
molecules. At low temperature, water molecules surround the chitosan chains. Heat 
increases the entropy of the chitosan solution, inducing chitosan to release protons. 
Consequently, the removal of hydrating water around chitosan molecules increases 
interactions between chitosan molecules. If there are sufficient phosphate groups 
accepting protons, sol-gel transition occurs [Chenite 2000, Cho 2005, Ta 2008]. This 
explains why dialyzed chitosan solution (DCh) requires lower concentrations of β-GP 
than the undialyzed chitosan solution for the sol-gel transition. 
  
 In general, the gelation of the injectable chitosan gel can be controlled by the 
degree of deacetylation of chitosan, concentration of chitosan, the amount of polyol salt, 
temperature, and the final pH of the gel forming solution [Ta 2008]. In the present study, 
the gelation of the chitosan formulation was more dependent on the final pH rather than 
the concentration of the β-GP solution. The chitosan solutions containing both high 
concentration (1.155 M) of β-GP and low concentration (0.088 M) of β-GP could induce 
thermal gelation around body temperature because their final pH values were around 7.2. 
Gelation of the chitosan/β-GP system was affected by a combination of the final pH, 
gelation time, and temperature. In addition, the rheological analysis also demonstrated 
that hydrophobic interactions played the most important role in the gelation of the 
chitosan/ β-GP solution [Chenite 2000, Cho 2005, 2006]. Generally, the strength of the 
gel is determined by the magnitude of the storage modulus (G’) or the great difference 
between the storage modulus (G’) and the loss modulus (G”). The result showed that the 
chitosan solution containing a higher concentration (1.155 M) of β-GP showed a lower 
storage modulus (G’), probably due to lower hydrophobic interaction between chitosan 
chains. This result indicated that the ionic interaction between ammonium groups of 
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chitosan and phosphate groups of β-GP did not significantly affect the thermal gelling 
mechanism [Cho 2005]. 
 
 The release of ellagic acid from the chitosan/β-GP gels is thought to take place 
by diffusion and could be accelerated by enzymatic degradation. This study showed that 
the loaded ellagic acid also affected the organization of the chitosan/β-GP gel network 
resulting in slower degradation rate of DCh/β-GP/EA0.1 than that of chitosan/β-GP gel. 
This result suggested that ellagic acid might be involved in the formation of chitosan/β-
GP gels and bind to chitosan molecules via ionic crossliking. However, chitosan/β-GP 
gels loaded with higher concentrations of ellagic acid showed faster degradation rates. 
This result was different from the previous study about Ch/EA composite films. As 
discussed in chapter 4 [Kim 2009], the in vitro enzymatic degradation behavior of the 
Ch/EA composite films was ellagic acid concentration dependent. The composite films 
with a higher weight percentage of ellagic acid exhibited slower degradation rates. This 
might be because ellagic acid was conjugated with the chitosan polymer via covalent 
bonds or ionic forces and embedded into the chitosan polymer network. However, this 
study showed that the addition of the β-GP solution changed the degradation rate due to a 
different mechanism of polymerization. This result may be because the main driving 
force for gelation is the hydrophobic effect rather than ionic crosslinking [Cho 2006]. The 
ellagic acid in the Ch/β-GP/EA1 was mostly entrapped along chitosan molecules 
physically and released fast when the chitosan/β-GP gel was swollen under acidic 
conditions. As a result, the Ch/β-GP gel degrades faster than the Ch/EA composite film 
along the pores of the Ch/β-GP gel and could be accelerated by an enzymatic activity. In 
addition, the morphological observation of the lypholized gels revealed different pore 
structures in the gel in the presence and absence of ellagic acid. The difference in pore 
texture is due to incorporation of ellagic acid into the Ch/β-GP gel. This porous structure 
of the Ch/β-GP gel is obviously different from the surface morphology of the composite 
film. Structural conformation of a material plays a significant role in the release of drugs 
[Ta 2009]. Therefore, the diffusion rate of gel materials is greater than that of film. These 
results demonstrated that ellagic acid is released by a combination of diffusion through 
pores as well as polymer matrix degradation. 
 
 The findings of this study also demonstrated that the concentration of β-GP 
significantly influenced the cell viability. To begin the sol-gel transition thermally, it is 
necessary to neutralize an acidic chitosan solution by adding a certain amount of β-GP up 
to the physiologically acceptable pH range. As shown in the cell viability results, 
however, high concentration of β-GP significantly reduced cell viability, indicating the 
toxic effect of the β-GP solution [Hoemann 2007]. 1.155 M o f β-GP solution was 
required to increase the pH of an acidic chitosan solution up to a pH of 7.2, at which the 
chitosan solution underwent thermal gelation at 37°C. In the present study, a dialysis 
membrane was used to increase the pH of an acidic chitosan solution before adding the β-
GP solution. Accordingly, neutralization of the acidic chitosan solution could reduce the 
concentration of β-GP to reach pH 7.2, resulting in improved cell viability as well as 
thermal gelation at 37°C.  
 
 Cell adhesion, growth, and proliferation on the material surface are sequential 
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responses which are essential for cell survival and function [Dubin-Thaler 2004, Aplin 
2002]. Cells are influenced by several factors in their environment. These contain 
chemical and physical interactions with neighboring cells and the extracellular substrate 
as well as chemical factors in the serum. As shown in Figure 5.9, the morphological 
changes of cells reflected their cellular response to the environmental materials. The cells 
on the bottom of well plates changed their morphology from a circular shape to spindle-
like features over time, while cells encapsulated inside the gel remained in their initial 
round shape but were still viable. This result suggests that the chitosan/β-GP gel was 
biocompatible and allowed cells to remain viable until they reached the rigid surface, 
allowing them to move, grow, and proliferate.  
 
 As shown in the study of the anti-tumor activity, the chitosan/β-GP gel loaded 
with ellagic acid could inhibit the growth of cancer cells in an ellagic acid concentration 
dependent manner. This result was consistent with previous studies, showing the anti-
proliferative effect of the Ch/EA composite films against skin and brain cancer cells [Kim 
2009]. The Ch/EA composite films could induce the accumulation of the tumor 
suppressor protein p53 and increase caspase-3 activation, which preceded an induction of 
apoptosis. The findings from studies of the Ch/EA composite films showed the anti-tumor 
activity of ellagic acid via a local delivery system with a surgical procedure for 
implantation. In the present study, ellagic acid was delivered via an injection of a liquid 
formulation. The results of this study demonstrated that a heat-induced chitosan gel could 
deliver the anti-cancer activity of ellagic acid and be considered as a promising delivery 
method for a local chemotherapy. 
 
 
5.6 Conclusion 
 
 This study was designed to develop a chitosan/β-glycerophosphate (β-GP) gel to 
deliver ellagic acid via a simple injection and effectively prevent local recurrence of 
cancer cells. The chitosan/β-glycerophosphate (β-GP) solution formed heat-induced gel 
network at body temperature, and the gelation temperature and time were affected by the 
final pH of the chitosan/β-GP solution. The ellagic acid was released from the chitosan/β-
GP gels by pores of gel network as well as polymer matrix degradation. A dialyzed 
chitosan solution could improve biocompatibility, indicated by 4 times higher cell 
viability than undialyzed chitosan gel at 3 days culture. Viability of U87 cells and C6 
cells cultured on chitosan gels containing 1% (w/v) of ellagic acid were lower than the 
same cells on chitosan gels at 3 days incubation by 3.8 times and 6.5 times, respectively. 
Therefore, the chitosan/β-GP gels loaded with ellagic acid could inhibit the cancer cell 
growth in an ellagic acid concentration-dependent manner. This study has demonstrated 
that the chitosan/β-GP delivery system is a promising biomaterial for cancer treatment as 
a local chemotherapy. 
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CHAPTER 6. DISCUSSION 
 
 
6.1 Overall Goals 
 
 The objective of this project was the utilization of ellagic acid using an 
implantable chitosan polymer for a sustained local delivery. It was hypothesized that 
chitosan/ellagic acid composite materials have anti-cancer activity at targeted sites by 
inducing apoptotic death and inhibiting angiogenesis. This chapter summarizes the 
specific findings of each study with regard to hypotheses in Chapter 2. Section 6.2 
discusses development and characterization of chitosan/ellagic acid composite films in 
terms of chemical structure, crystallinity, surface morphology, degradation behavior, and 
release profile. Section 6.3 discusses in vitro anti-cancer activity of chitosan / ellagic acid 
composite films. This section emphasizes anti-cancer activity of the composite films via 
direct or indirect culture and potential anti-cancer mechanisms. Section 6.4 discusses in 
vivo anti-cancer activity of composite films using a glioma brain cancer model. Anti-
cancer activity of the composite film is evaluated and compared with control groups. 
Section 6.5 discusses a thermo-sensitive injectable gel for the delivery of ellagic acid. 
This section emphasizes thermal gelation of chitosan polymer and biocompatibility of the 
delivery system. Finally, section 6.6 provides conclusions of this project.   
 
 
6.2 Development of the Chitosan/Ellagic Acid Composite Films 
 
 Chitosan/ellagic acid composite films were fabricated to utilize the anti-cancer 
properties of ellagic acid at local targeted sites. It was hypothesized that ellagic acid is 
chemically attached and embedded into chitosan polymer, expressing a new form of 
ellagic acid. In order to test this hypothesis, chitosan/ellagic acid composite films were 
characterized using FTIR, SEM, water contact angle, and XRD. Their degradation 
behavior and release profiles were investigated. These investigations provided the 
information regarding surface chemistry and morphology of the composite films. Studies 
of surface chemistry indicated that there exist chemical reactions between chitosan and 
ellagic acid, including amide and ester linkages. This is because the carboxylic groups of 
the ellagic acid combined with the hydroxyl and amine groups of the chitosan [Tien 2003, 
Wang 2004]. The surface roughness and wettability of the composite films were 
significantly affected by concentration of ellagic acid. Composite films became rougher 
and more hydrophilic compared with the chitosan film. In addition, crystal structure of 
ellagic acid was observed with increasing concentration of ellagic acid. These findings 
suggested that ellagic acid was chemically bound and physically entrapped into the 
chitosan network, and its functional groups such as hydroxyl and carboxyl groups 
influenced surface chemistry [Amaral 2006, Neamnark 2007]. These results support 
hypothesis 1. 
 
 A major target in local drug delivery is to overcome an initial burst effect, 
leading to a rapid loss of drug efficacy and distributing toxicity non-specifically into body 
[Dash 1998, Park 1996]. Drug release from polymeric delivery system is governed by 
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polymer composition, polymer characteristics, polymer degradation, drug loading, drug 
solubility, and drug/polymer interactions [Gunatillake 2003]. In vitro release profiles of 
the ellagic acid clearly demonstrated a sustained slow release of ellagic acid without an 
initial burst release. The chitosan/ellagic acid composite films were biodegradable by 
enzymatic hydrolysis. In this regard, the presence of lysozyme accelerated the release 
profile of ellagic acid compared with the absence of lysozyme. Some characteristics of 
chitosan and ellagic acid such as solubility, DDA of chitosan, and chitosan/ellagic acid 
interactions contributed to the sustained slow release of ellagic acid from composite films. 
The degradation rate of chitosan films can be slowed down by using a chitosan polymer 
with high degree of deacetylation (DDA) and molecular weight [Li 2007, Wang 2006]. In 
addition, ellagic acid is slightly soluble in medium at pH 6.0. These results support 
hypothesis 2. The findings from these studies suggest that the release profile of ellagic 
acid is governed by chitosan characteristics, degradation, chitosan/ellagic acid 
interactions, ellagic acid loading, and solubility.  
 
 
6.3 In vitro Anti-Cancer Activity of Composite Films 
 
 It was hypothesized that the chitosan/ellagic acid composite films inhibit growth 
of cancer cells in an ellagic acid concentration dependent manner. In order to test this 
hypothesis, viable cancer cells and their activities were monitored on the composite films. 
Studies of anti-cancer activity indicated that composite films lead to cancer cell death in 
an ellagic acid concentration-dependent manner. The morphological changes of cancer 
cells cultured on composite films reflected a direct cellular response to the composite 
films. Cell adhesion, growth, and proliferation correspond with cell survival and function 
[Findlay 2002, Willingham 1999]. Cancer cells cultured on chitosan films containing 0, 
0.05, and 0.1 % (w/v) of ellagic acid initially aggregated, indicating initial inhibitory 
effect of composite films. However, after 3 days incubation, cancer cells survived and 
spread, suggesting these composite films could not induce anti-cancer activity. Initial 
inhibitory effect of the composite films is probably due to the combination effect of 
chitosan and ellagic acid. Some evidences suggested that chitosan induces anti-bacterial 
and anti-tumor properties attributed to the tumor necrosis factor-α (TNF- α) in human 
monocytes [Muzzarelli 1997, Ravi Kumar 2006]. In contrast, cancer cells cultured on 
chitosan films containing 0.5 and1 % (w/v) of ellagic acid remained in the initial round 
shape and could not grow and proliferate, indicating anti-cancer activity of composite 
films in an ellagic acid concentration dependent manner, thus supporting hypothesis 3.  
 
 In order to test hypothesis 4 stating that chitosan/ellagic acid composite films 
localize therapeutic effect via slow release of ellagic acid, anti-cancer activity of 
composite films was monitored via indirect cell culture. This study demonstrated cancer 
cells in the absence of direct contact with the composite film significantly proliferated, 
indicating the slow release of the ellagic acid into the cell culture media. This result is 
consistent with the release study in section 6.2. This localized effect was also monitored 
by observing cell morphological changes at the interface of the composite films in 
chapter 3 [Kim 2009]. However, there exists significant difference between a chitosan 
film and a chitosan film containing 1 % (w/v) of ellagic acid, indicating the effect of 
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released ellagic acid into culture medium. These findings support hypothesis 4.  
 
 The anti-cancer mechanism of the chitosan/ellagic acid composite films was 
investigated in chapter 3 and 4. It was hypothesized that the composite films have anti-
cancer activity by inducing apoptosis of cancer cells and suppressing angiogenesis [Khan 
2007, Labrecque 2005]. The results demonstrated that the chitosan/ellagic composite 
films induce apoptotic cell death via accumulation of the tumor suppressor protein p53 
and increase in caspase-3 activation. These investigations suggest induction of apoptosis 
by the composite films would minimize inflammatory effects causing the damage in the 
surrounding tissue. In addition to the apoptosis mechanism, the tube formation of 
endothelial cells was monitored to investigate the ability of the composite films to inhibit 
angiogenesis. The results showed that the composite film (Ch/EA1) inhibits 
morphological differentiation of the HUVEC, indicating the effect of the composite film 
on suppressing angiogenesis. These findings support hypothesis 5.  
 
 
6.4. In vivo Anti-Cancer Activity of Composite Films in a Glioma Model 
 
 It was hypothesized that a composite film delivers anti-cancer activity of ellagic 
acid effectively in a local glioma tumor model. Studies of the glioma animal model were 
designed according to preliminary data and literature reviews. Some evidences suggested 
that the significance of the effect depends on time at which treatment was initiated [Au 
2001, Bello 2002, Giussani 2003]. In this study herein, the treatment group (Ch/EA20) 
was implanted subcutaneously on the fifth day after tumor inoculation. At this point, the 
tumors were small and visually detectable. A preliminary animal study, in which the 
treatment group (Ch/EA10) was implanted on the eleventh day after tumor inoculation, 
demonstrated there was no significant difference between a control group and a treatment 
group. This result suggests the significant effect corresponds with initial treatment time 
and ellagic acid loading. The findings of this animal study verified that the treatment 
group (Ch/EA20) significantly delayed tumor growth compared with an untreated group 
and a chitosan control group. In addition, severe weight loss of animals was not observed 
in all the groups. The histological analysis also confirmed the efficacy and safety of the 
Ch/EA composite film at the local area. This result can be attributed to the slow and 
localized release of ellagic acid as discussed in section 6.3. These findings support 
hypothesis 6. 
 
 
6.5 Injectable Chitosan Gel Delivery System 
 
 A chitosan based injectable hydrogel was investigated in terms of thermal 
gelation, biocompatibility, and anti-cancer activity. This study was designed to deliver 
ellagic acid via an injection of a liquid formulation. It was hypothesized that a liquid 
chitosan formulation forms a heat-induced chitosan gel at body temperature and delivers 
the anti-cancer activity of ellagic acid. A β-glycerophosphate (β-GP) was employed in 
this study for induction of thermal gelation of chitosan solution. Several interactions 
during the gelation process are involved, including the loss of electrostatic repulsion, 
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hydrogen bonding, and increased hydrophobic interaction. It was postulated that main 
driving force for gelation is the hydrophobic effect rather than ionic crosslinking [Cho 
2006]. The findings of this study suggest that thermal gelation is governed by the pH of 
the chitosan/β-GP solution and occurs at body temperature supporting hypothesis 7. 
Additionally, this injectable gel is biocompatible and biodegradable. The release profile 
of ellagic acid from the chitosan gel represents sustained slow release and can be 
accelerated by an enzymatic activity. The chitosan/β-GP gels loaded with ellagic acid 
inhibited cancer cell growth in vitro in an ellagic acid concentration-dependent manner. 
These results support hypothesis 8. These findings of this study suggest that injectable 
chitosan/β-GP gel is a promising delivery method as a local chemotherapy. 
 
 
6.6 Conclusion 
 
 This project proposes an implantable polymeric delivery system for a sustained 
drug release and localized treatment. Chitosan/ellagic acid composite materials have been 
studied with respect to a local anti-cancer activity of ellagic acid in vitro and in vivo.  
 
 Composite films were fabricated for the sustained and slow release of ellagic 
acid via utilization of chitosan characteristics, chitosan/ellagic acid interactions, and 
ellagic acid concentration. From studies of composite films, it was observed that ellagic 
acid was incorporated into chitosan polymer and its anti-cancer activity could be 
localized in a dose-dependent manner. Localized effect of ellagic acid corresponds with 
slow release of ellagic acid into surrounding environments, inducing less toxic effect. It 
was postulated that anti-cancer mechanism of ellagic acid includes apoptosis and anti-
angiogenesis. These studies demonstrated that the chitosan/ellagic acid composite films 
induce anti-cancer activity by inducing apoptotic death and inhibiting angiogenesis in an 
ellagic acid concentration dependent manner.  
 
 To further improve the delivery method, studies of a chitosan base injectable gel 
were performed using β-glycerophosphate salt (β-GP) for a local delivery of ellagic acid. 
The results demonstrated that the thermal gelation occurs at body temperature via 
hydrophobic interactions between chitosan molecules. Sol-gel transition was dependent 
on the pH of the gel formulation and temperature. The chitosan/β-GP gel delivery system 
was biocompatible and could induce anti-cancer activity via a sustained release of ellagic 
acid. In conclusion, the chitosan/ellagic acid composite material is an implantable 
delivery system and provides sustained local therapy for cancer treatment. 
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CHAPTER 7. FUTURE DIRECTIONS 
 
 
 The chitosan/ellagic acid composite materials herein showed as a promising local 
delivery for cancer treatment. However, most studies have been performed on a short 
term basis and therefore future experimental designs should be undertaken to determine 
the long term effects of these materials with regard to release profile, degradation 
behavior, and biological properties. The composite films degraded slowly with increasing 
concentration of ellagic acid. This may be desirable for a sustained release, but it may 
cause a long term complication in the normal tissue if it does not degrade completely 
after a therapeutic span. Generally, biodegradation of the polymeric delivery systems 
depends on polymer structure, composition, morphology, surface structure, molecular 
weight, shape, size, and etc [Dash 1998, Jain 2000]. The degradation of the composite 
materials, in this research, was governed by characteristics of chitosan, concentration of 
ellagic acid, chitosan/ellagic acid interactions, and fabrication methods (film or gel). 
Those factors are controllable and their changes may significantly affect the release rate 
and the biological properties of the composite materials. Therefore, further studies are 
required to investigate the optimal conditions according to the applications.   
 
 In view of the anti-cancer activity, the phenolic compounds including ellagic acid 
may be considered promising pharmaceutical agents in the future because of their drug-
like effects on human body. But, they are poorly absorbed into the body due to the limited 
bioavailability and high metabolism in human [Rahman 2006, Scalbert 2000]. From this 
research, the incorporation of the ellagic acid into the chitosan polymer could extend the 
use of biological properties of ellagic acid by delivering a specific local site. Therefore, it 
is necessary to establish the therapeutic strategies for the delivery of the phenolic 
compounds against human diseases including cancer. In fact, studies on identifying the 
mechanism of the action for the phenolic compounds in the local delivery may lead to 
new therapeutic targets.   
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